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Abstract
Colo recta l cancer (CRC) is a major health concern in the Canadian province of
Newfou ndland and Labrador (NL), as this population has the second highest incidence of
CRC in North America . Previous mutatio n analysis in the NL CRC popula tion has
revealed that the high frequency of hereditary CRC in NL is likely attribu table to novel
suscep tibility genes. A recent study suggests that N-acetylgala ctosaminyltransferase 12
(GALNT12) may be a novel gene associate d with CRC suscepti bility . The purpose of this
study was to investigate the impact of GALNT 12 germli ne variants in CRC families from
NL and in 481 cases from the Newfoundland Colorectal Cancer Registry (NFCC R) with
an unknown molecular basis for their disease.
GALNT 12 was first sequenced in 129 CRC families to investigate if varian ts
within this gene segregate with the disease. Probands included in the study have a high
family incidence of CRC and were referred to the Provincial Medical Genetics Program.
DNA from 481 patients from the NFCC R was also sequenced in exons 4 and 6 to identify
causal variants.
Two putatively pathogenic variants were identified in the GALNT1 2 gene within
four clinica l family probands - c.907G>A, p.Asp303Asn (three probands), and
c.1187A>G, p.Tyr396Cys. Two families showed partial segregation ofc.907G>A with
CRC or adenomas. The c.907G>A varian t was identified in an additional two cases after
sequencing 481 cases from the NFCC R. Another variant, c.889C >T, was also identified
that was previously reported in a CRC case . This study provides some support for the
association between GALNT12and CRC susceptibility and suggests that further
investigations should be performed .
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Chapter 1
1.0 Colorectal Cancer Literature Review
1.1 Colorectal Cancer: An important health risk
Colorectal cancer (CRC) is the third most common form of cancer in developed
countries and is diagnosed in approximately 22,550 Canadians annually (Canadian
Cancer Society , 2011) . CRC is the second leading cause of cancer-related death in
Canada, killing an estimated 5,000 men and 4,100 women each year (Canadian Cancer
Statistics, 2011). The lifetime risk of developing CRC is approximately 6-7% (Canadian
Cancer Statistics, 2011) .
Approximately 20% of all colorectal cancer cases can be attributed to an inherited
predisposition (Kemp et aI, 2004) . There are several known forms of hereditary CRC
which contribute to 2-6% of all CRC (Kemp et aI, 2004) ; the most common include
Lynch syndrome (LS), familial adenomatous polyposis (FAP) and MUTYH-associated
polyposis (MAP) .
1.2 Hereditary Colorectal Cancer
1.2.1 Lynch Syndrom e
Lynch Syndrome (LS) is an autosomal dominant genetic predisposition to colon
and extra-co lonic cancers caused by pathogenic variants in the mismatch repair (MMR)
genes (Bellinzzi and Frankel , 2009). LS is the most common form of hereditary
colorectal cancer, accounting for 2-5% of all CRC (Lynch, et aI., 2009).
In 1966, Henry Lynch and his team of researchers investigated two large families
that had a strong family history of CRC which lacked multiple colonic polyps . It was also
noted that a variety of extra-colonic cancers were observed in these families . This
syndrome was originally named "cancer family syndrome" and was later referred to as
hereditary non-polyposis colorectal cancer (HNPCC) (Lynch et aI., 2009). Hereditary
CRC that is associated with pathogenic variants in the MMR genes is now referred to as
Lynch Syndrome. HNPCC includes LS but also refers to a syndrome with a similar
phenotype of unknown genetic etiology (Lynch et aI, 2009). While CRC is the most
frequent cancer observed in LS, there is also an increased risk of developing multiple
extra-colonic cancers including endometrial , ovarian, small bowel , stomach, pancreatic ,
kidney, ureter, hepato-biliary, and brain cancers (Lynch et aI, 2003).
Pathogenic variants within the DNA MMR genes (MSH2, MLHl, MLH3, MSH6,
PMS2) are the genetic changes that cause LS. The MMR process protects cells against
DNA errors that arise during replication and recombination (Hsieh & Yamane, 2008).
Mutations during replication occur at a rate of 10,10to 10'9nucleotides per cell division
(Iyer et aI., 2006) . The MMR genes code for protein products which are responsible for
the post-replicative identification and repair of mismatched nucleotides or small
insertions /deletions within DNA. This process is highly conserved from prokaryotes to
eukaryotes (lyer et aI., 2006). Individuals with only a single functional copy of a
particular MMR gene are vulnerable to insufficient MMR activity ifthere is a somatic
mutation of the second copy within a cell. Inactivation ofMMR proteins involved in the
MMR process significantly increases the number of spontaneous mutations occurring in
the cell, increasing the risk of developing cancer in the colon and other extra-colonic
tissues associated with LS (Kolodner, 1996).
To date there are five MMR genes identified in which variations have been shown
to cause LS: MSH2, MLH1, MLH3, MSH6, and PMS2. MLHl and MSH2, account for
80% of the known LS pathogenic variants (Woods et ai, 2007) . Jenkins and colleagues
(2006) investigated the cancer risk for individuals harbouring MMR pathogenic variants .
They determined that the cumulative risk for developing CRC by age 70 was 45% (range
29%-62%) for men and 38% (range 19%-51%) for women.
Risk criteria for classifying families at high risk for LS were developed in 1991
by the International Collaborative Group on HNPCC (ICG-HNPCC) . As the meeting was
held in Amsterdam , Holland , the criteria became known as "Amsterdam Criteria " (AC-I ,
see appendix A). At this time, the MMR genes associated with LS had not been
identified ; therefore , AC-I was used to help select families ideal for linkage studies. A
modified set of criteria were developed by the same collaborative group in 1999, which
were more sensitive to the presence of extra-colonic cancer s observed in LS (AC-II , see
appendix A). Additional measures were developed to identify individuals at risk for LS.
The Bethesda Criteria (Rodrigues-Bias et ai, 1997) and the Revised Bethesda Criteria
(Umar et ai, 2004) were developed to identify individual s who should be screened for the
classical molecular markers of LS including microsatellite instability and MMR protein
deficiencies in somatic tumour tissue. See appendix B for the complete Revised
Bethesda Criteria .
1.2.2 Familial Adenomatous Polyposis and Attenuated Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) is a colon cancer syndrome that is
characterized by the presence of hundreds to thousands of colonic polyps by the second
or third decade of life (Nieuwenhuis & Vasen, 2007). FAP is caused by deleterious
germline variants in the adenomatous polyposis coli (APC) gene and is inherited in an
autosomal dominant fashion (Nieuwenhuis & Vasen, 2007). About I in 5,000-10,000
individuals are affected by FAP ( Kinzler & Vogelstein, 2002) . FAP accounts for < 1%
of all CRC (Bisgaard et aI, 1994).
A clinical diagnosis ofFAP is given when more than 100 colonic polyps are
identified, however, the actual number of polyps may be greater than 1000 (Bussey ,
1975). Due to the large number of polyps developing at a relatively young age in FAP
patients, the onset of CRC by the age of 40-50 years is almost inevitable (Bussey , 1975).
Sigmoidoscopic screening is recommended by age 10 - 12 years for individuals
harbouring APC pathogenic variants and a preventative colectomy is usually
recommended by 20 years of age (Vasen, 2000).
The clinical phenotype associated with FAP is not limited to CRC. It also includes
dental abnormalities, congenital hypertrophy of the retinal pigment epithelium, lipomas,
epidermoid cysts, osteomas, upper gastrointestinal polyps and desmoid tumours (Bussey,
1975). FAP patients are also at an increased risk for developing cancers of the
duodenum, brain (medulloblastoma), thyroid and hepatobiliary tract (Bussey, 1975).
The chromosomal instability pathway underlies the development of FAP caused
by pathogenic variants in the APC gene (Miyoshi et aI., 1992). This gene is located on
chromosome 5q21-22 and consists of 15 exons (Kinzler et ai, 1991). APC is a tumour
suppressor gene and is involved in many cellular processe s such as cell migration ,
differentiation, transcription and apoptosi s (Goss & Groden, 2000 ; Sieber et ai, 2000).
FAP patients have one germline causal variant in APC within every cell. Some cells can
acquire a second somatic mutation or loss of the other allele . A tumour develops from
these cells that have acquired a second somatic insult of the APC allele . This follows
Alfred Knudson's "two-hit hypothesis " of cancer developing from cells that have
accumulated DNA damage (Knudson , 1971).
Pathogenic variants occurring within the 5', 3' or exon 9 regions of the APC gene
are known to cause a less severe phenotype compared to FAP, called Attenuated Familial
Adenomatous Polyposis (AFAP) (Sieber et ai, 2006) . Pathogenic variants associated
with AFAP do not affect the APC protein function as severely as FAP pathogenic
variants , thus explaining the attenuated phenotype . Patients with AFAP may have fewer
polyps (lOs-IOOs) than those with classic FAP and also may have a later onset ofCRC;
however , the phenotype can be quite variable (Sieber et ai, 2006).
1.2.3 MUTYH-a ssociat ed polyposis : The MUTYH gene
MUTYH-associated polyposis (MAP) is an autosomal recessive condition
associated with deleterious variants in the MUTYH gene (AI-Tassen et ai, 2002). MAP is
associated with an increased risk for the development ofCRC (Cheadle and Sampson,
2007) and the clinical phenotype of MAP overlaps that of AFAP (10-100 adenomas) and
FAP (>100 adenomas).
MAP was recently recognized in 2002 by AI-Tassen and colleagues and its
prevalence, natural history and full phenotype are still being defined (Sampson & Jones ,
2009). Previous studies that conducted genetic testing for common deleterious variants
underlying MAP (p.Tyrl79Cys and p.Gly396Asp) indicate that approximately 1% of all
CRC cases from Western Europe and North America are associated with this condition
(Croitoru et ai, 2004; Fleischmann et ai, 2004; Wang et ai, 2004; Farrington et ai, 2005) .
Biallelic pathogenic variants in the MUTYH gene are responsible for the
development of MAP. The MUTYH gene produces a protein involved in the oxidative
damage repair pathway . MUTYH is a base-excision repair DNA glycosylase that forms a
complex with MSH2IMSH6 which functions to help protect cells against the negative
mutagenic effects from oxidative damage (Cheadle & Sampson, 2007) . Oxidative
damage from reactive oxygen species within the cell can produce 8-hydroxyquanine (8-
OxoG) from guanine, one of the most stable products formed from oxidative damage
(Cheadle & Sampson, 2007). DNA glycosylases are important for excising adenines
improperly paired with 8-0xoG instead of cytosine. Failure to correct this error within
the DNA, due to pathogenic variants in the MUTYH gene producing a non-functional
protein , are thought to lead to the hallmark characteristic of the APC G:C--+T:A
pathogenic variants occurring within MAP tumours (Ames & Gold, 1991).
1.2.4 Familial Colorectal Cancer Type X fFCCTXI
Familial colorectal cancer type X (FCCTX) is a term used to describe families
that meet the Amsterdam I criteria (AC-I) yet do not have signs of a MMR defect (see
Lynch syndrome above) . The AC-I and AC-II were created in 1991 and 1999
respectfully, to help identify families with hereditary nonpolyposis colorectal cancer
(HNPCC); HNPCC was earlier described by Dr. Henry Lynch as an autosomal dominant
syndrome, associated with an increased risk for CRC with an early age of onset (20 years
earlier than non-familial CRC) and an increased probability of cancer on the right side
compared to sporadic cases . Extra-colonic cancers are also associated with HNPCC
including cancers of the stomach, endometrium, small intestine, kidney, ureter, ovary and
hepatobiliary tract (Lynch et aI., 2009) .
The underlying genetic cause ofHNPCC was unknown at the time the AC-I and
AC-II were created; however , the application of these criteria was instrumental in
identifying and characterizing families for studies which lead to the identification of
germline mutations in the MMR genes. "Lynch syndrome" is now used to describe
families that harbour MMR gene mutations and the term "Familial Colorectal Cancer
Type X" was then assigned to those families that fulfilled AC-I that did not have a DNA
mismatch-repair defect identified (Lindor , 2009) . The "X" was used to illustrate the
unknown etiology of the condition , genetic or otherwise . There has been a call to retire
the term HNPCC , since the identification of the involvement of the MMR genes, as it has
been improperly used to describe Lynch syndrome (Jass, 2006) .
According to Lindor (2009) , "FCCTX is a heterogeneous grouping of: (I) random
congregations of a common tumour within a family; (2) congregations of a tumour
related to shared lifestyle within a family; (3) polygenic predisposition ofa family; (4)
some undefined monogenic conditions. "
Several studie s on FCCTX have furthered knowledge about the characteristics of
this disorder . It has been shown that there is an older age of onset of CRC in FCCTX
cases compared to that of LS cases (55 years verses 41 years) (Mueller-Koch et aI.,
2005; Dove-Edwin et aI., 2006; Valle et aI., 2007). FCCTX tumours are more often left
sided, compared to LS cases, and FCCTX cases have a greater adenom a/carcinoma ratio
(Mueller-Koch et aI., 2005) . A study of 64 Spanish families that fulfilled AC-I confirmed
a later age of onset in FCCTX patients and additionally noted that FCCTX patients were
more likely to have left-sided, mucinous tumours and less likely to have multiple primary
tumours compared to LS (Valle et aI., 2007). It is not known whether FCCTX patients are
at risk for the development of extra-colonic cancers. It is important to note that the group
of families categorized as having FCCTX are likely a genetically heterogeneous group ,
with various genetic entities responsible for the hereditary CRC in the different families
(M.O. Woods, personal communication , May 2011).
1.2.5 Other Colorectal Cancer Syndromes and Associated Genes
Other than the more common hereditary CRC syndromes , there are other rare
cancer syndromes that are associated with known genes contributing to hereditary CRe.
Turcot's syndrome is a clinical diagnosis defined by brain tumours as well as polypo sis
and/or CRe. This includes families with medulloblastoma and APC mutations, and also
families with MMR mutations where the brain tumour is a glioma or astrocytoma
(Hamiltonetal.,1995).
Muir-Torre syndrome is a particular subgroup ofLS where sebaceous cancers of
the skin occur in addition to the other manifestations ofLS. Similar to other LS tumours ,
sebaceous cancers of the skin are also characterized by microsatellite instability (Entiu s et
aI., 2000). Pathogenic variants in the MMR genes MSH2 and MLHJ are responsible for
the occurrence of this condition . Muir-Torre Syndrome follows an autosomal dominant
mode of inheritance, is highly penetrant and has variable expression (Prieto, 2011) .
Constitutive MMR deficiency is a separate sub-type of CRC and is caused by
biallelic pathogenic variants in the MMR genes. Individuals who inherit homozygous or
compound heterozygous mutations develop cancer within the first 10 years of life (Felton
et aI., 2007) . The age of onset for these malignancies generally depends on the severity of
the MMR mutation. Pathogenic variants that produce an MMR protein with a complete
loss of function usually present with brain and hematological cancers in early childhood
(Felton et aI., 2007). Individuals that inherit biallelic missense mutations with residual
function may present with gastrointestinal cancers or neurofibromas of the skin and
tongue within the first decade of life (Felton et aI., 2007). Cafe-au-lair spots are usually
present in all individuals that possess biallelic pathogenic variants in any of the MMR
genes regardless of the level of residual MMR function (Felton et aI., 2007).
Peutz-Jeghers syndrome is characterized by hamartomatous polyps in the
gastrointestinal tract and mucocutanous melanin pigmentation, particularly of the lips and
oral mucosa. It follows an autosomal dominant pattern of inheritance, incomplete
penetrance and variable expression. Individuals with Peutz-Jcghers syndrome are at an
increased risk of developing gastrointestinal and non-gastrointestinal tumours (Giardiello
& Trimbath, 2006). STKJJ (also known as LKB]) has been implicated in 30-70% of
sporadic cases of Peutz-Jeghers syndrome and has been responsible for up to 70% of
cases with a family history of this condition (Amos et aI., 2004). Screening programs for
those at risk have now been implemented through genetic testing of the STKJJ gene .
Ongoing studies have attempted to identify the additional genetic entities
underlying a significant proportion of unsolved hereditary CRC families. These studies
have revealed several genes associated with the disease . A study by Frio and colleagues
(20 I0) found homozygous BUBIB splice-site variants in an individual diagnosed with an
adenocarcinoma of the ampulla of Vater at 34 years of age, adenomatous polyps 20 years
later, and by multiple primary invasive adenocarcinomas within the colon and the
stomach . This homozygous variant created a de novo splice site affecting the proper
transcription of the gene. BUBRI, encoded by BUBIB, is important for regulation of the
spindle assembly checkpoint during mitosis. It has also been noted that APC and BUBR I
both work together to regulate mitotic cell division (Kaplan et aI., 2001). Biallelic
pathogenic variants of the BUBIB gene had been initially associated with mosaic
variegated aneuploidy syndrome and the chromosomal instability pathway. Individuals
with mosaic aneuploidy syndrome have growth deficiencies, microcephaly, mental
retardation, abnormalities of the central nervous systems and physical dismorphic
features in addition to cancer (Garcia-Castillo et aI., 2008) . The case study presented by
Frio and colleagues (2010) identified a specific homozygous change affecting the splice
site and the proper transcription of the BUB1B gene. This homozygous change was
associated with a phenotype of adenomatous polyps and multiple adenocarcinomas
within the colon and stomach. This phenotype is hypomorphic compared to those
mentioned above, which are known to be associated with other biallelic pathogenic
variants in the BUBIB gene.
Recently, pathogenic variants in BMPRIA have been found in some families that
were classified as FCCTX (Nieminen et aI, 2011). After genome-wide linkage analysis
IO
was conducted on a family with high a priori informativeness, a maximal LOD score of
1.6 was determined for marker DJOS1686 which is mapped to chromosome IOq23.
Sequencing of BMPR1A revealed a gennline tri-nucleotide deletion (c.264-266del,
p.Glu88del). This deletion segregated with the adenoma/carcinoma phenotype within a
family. Further sequencing in other FCCTX families revealed a proband with a 24-base
deletion within intron I affecting the 5' portion of exon 2 leading to a predicted skipping
of exon 2 and a subsequent frameshift (p.Gly23GlufsXI0), which was confirmed by
cDNA analysis. BMPR1A encodes a type I bone morphogenetic protein receptor that is
important for activation of SMAD transcriptional regulators . BMPR1A has been
previously implicated in juvenile polyposis syndrome.
Juvenile polyposis syndrome (JPS) is characterized by the presence of multiple
polyps in the gastrointestinal tract including the stomach, small intestine, colon and
rectum at a young age, typically by age 20 (Haidle & Howe, 2003). Most of the polyps
associated with JPS are benign; however, malignant developments can occur, increasing
the lifetime risk ofCRC up to 50% (Howe et al., 1998b). This syndrome has an
autosomal dominant mode of inheritance and the genes BMPR1A and SMAD4 have been
implicated with this disease. About 20% of individuals with this syndrome have a causal
variant in BMPR1A and an additional 20% have a SMAD4 deleterious change (Haidle &
Howe, 2003). These genes are investigated in molecular genetic testing for clinical and
genetic counseling purposes in the management of this syndrome .
1.3 Dietary and Environmental Factors Associated with Colorectal Cancer
Historically , it has been thought that poor (high-fat, low-fiber) diet has been
associated with the development of CRC, especially if the diet is coupled with a
sedentary lifestyle, excess caloric intake and other unhealthy habits such as smoking
and significant alcohol consumption (Doll et aI., 1981; Giovannucc i et aI., 1992).
While some studies have shown that high fat-low fiber diets are linked to an increased
risk of developing colorectal adenomas and carcinomas (Giovannucci et al., 1993;
Willett et al., 1990), a review of the literature from January 1966 to December 2006 has
indicated that many of the dietary influences on the development of CRC are not as well
defined as once thought (Ryan-Harshman & Aldoori , 2007) .
Studies that investigated the link between red meat and fiber consumption have
yielded variable results ; however, studies evaluating the link between CRC and the
intake of vitamin D, folic acid and calcium have been more reproducible (Ryan-
Harshman & Aldoori , 2007) .
Minerals such as folic acid, calcium and vitamin D may be an important role in
the prevention of colorectal adenomas (Giovannucci et al., 1993; Grau et al., 2003).
Furthermore , it has been shown that calcium and vitamin D may work together to
reduce recurrence of adenomas . Grau et al. (2003) found that dietary calcium levels
were not associated with the presence of adenoma s when vitamin D levels were at or
below average (29.1 ng/mL) and that a reduced risk of adenomas was only found among
individuals that were receiving calcium supplements.
Studies have shown that the regular use of aspirin is associated with a moderate
reduction in the risk of developing colonic polyps and CRC (Sandler et al., 2003 ; Baron
et aI., 2003; Benamouzig et al., 2003; Logan et al., 2008) . Burn and colleagues (2008)
investigated the effect of aspirin use on individuals with LS. They found that the use of
12
aspirin for up to 4 years had no effect on the development of colorectal adenomas or
carcinomas. An additional study was conducted by Rothwell et al. (20 I0) to determine
the long-term effectiveness of low aspirin doses on CRC incidence . They found that
aspirin, when taken for 5 years or longer, reduced the long-term incidence and
associated mortality ofCRC. Specifically , taking aspirin prevented cancer in the
proximal colon . A more recent study by Bum and colleagues (2011) found that
individuals that had a genetic predisposition to LS who took 600 mg of aspirin a day for
a mean period of 25 months had a significantly reduced incidence of cancer compared
to LS carriers that did not take any aspirin (placebo).
Overall, evidence has shown that diet has a moderate influence on the
development ofCRC (Ryan-Harshman & Aldoori , 2007) . It has been shown that
unhealthy lifestyles , such as smoking, low levels of physical exercise and excessive
alcohol consumption are associated with ill health including CRC (Chen et aI., 1999). A
review of the literature indicates a healthy diet that includes vitamin D, calcium and
folate may decrease the risk of developing CRC (Ryan-Harshman & Aldoori, 2007) . It
is very likely that an interaction between genetic factors and environment plays a
significant role in the onset of colorectal adenomas and carcinomas (Le Marchand,
2002; Chen et aI., 1999).
1.4 Colorectal Polyps and the Associated Risk ofColorectal Cancer
1.4.1 Colorectal Polyp Classifications
A colorectal polyp is defined as a fleshy growth or protrusion of cells that
occurs on the epithelial lining of the colon or rectum. Colorectal polyps can be broadly
categorized into three histological groups, neoplastic (adenomatous), non-neoplastic and
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sub-mucosal (Table 1.1) (Markowitz & Winawer , 1997). Neoplastic (adenomatous)
polyps are either pedunculated, with a stalk-like attachment to the wall of the colon or
rectum, or sessile, attached to the colon or rectum by a broad or flat base (Figure 1.1)
(Markowitz & Winawer, 1997). Identifying neoplastic polyps is important because of
their potential to develop into a malignant form. Although it is generally accepted that
most CRCs develop from a pre-existing adenomatous polyp, colorectal adenomas occur
in up to 50% the general population . Men have a higher frequency of adenomas
compared to women and the risk of developing these lesions increases with age (Rickert
et aI., 1979). Adenomas have been found to occur more frequently on the left side of the
colon, sharing the same anatomic distribution as CRe. Adenomas can be further
categorized as tubular , tubulovillious or villous . Tubular adenomas account for up to
approximately 80% of all adenomas (O'Brien et aI., 1990). All adenomas have some
degree of dysplasia; mild, moderate or severe (high-grade). The extent of dysplasia is
based on glandular architectural distortion and cytological epithelial atypia (Markowitz &
Winawer, 1997). The National Polyp Study determined that approximately 86% of
adenomas show mild dysplasia, 8% show moderate dysplasia and 6% show severe
dysplasia (or carcinoma in situ) . It was also noted that age, large polyp size and polyps
with a villous structure were associated with increased risk for severe dysplasia (O'Brien
et aI., 1990). Polyps can also be malignant, meaning that they contain malignant cells
which extend though the muscularis mucosa into the submucosa . Malignant polyps have
the potential to metastasize and occur in approximately 2% of all adenomas (O'Brien et
aI., 1990). It has also been noted that sessile polyps have a higher potential to metastasize
Tabl ef .l Histo logica l Categorizat ion of Colorectal Polyps
Neoplastic
Benign
Mild Dysplasia
Modera te Dysplasia
High Grade Dysplasia
Severe Dysplasia
Carcinoma in situ
Malig nant
Invasive Carcinoma
Non-Neoplastic
Hyperplastic
Mucosal
Inflammatory
Hamartomatous
Juvenile
Peutz-Jeghcrs
Submucosal
Lymphoid
Lipoma
Other
Adapted from Markowitz & Winawer (1997).
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Figure 1.1. Colorectal Polyps. a) pedunculated polyp b) sessile polyp . (Markowitz &
Winawer,1997).
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than pedunculated polyps , and are therefore treated more aggressively (Markowitz &
Winawer , 1997). Non-neoplastic polyps include hyperplastic, mucosal, inflammatory
and harmartomatous polyps. Hyperplastic polyps (HP) are the most frequent form of non-
neoplastic polyps, occurring in 20-30% of the general population (Vatn et al., 1982;
DiSario et al., 1991). Hyperplastic polyposis is a condition defined as having >20 HPs
(John Hopkins Colorectal Cancer , retrieved online). HPs were once thought to carry no
malignant potential (Markowitz & Winawer , 1997); however, Torlakovic and colleagues
(1996) found that individuals diagnosed with hyperplastic polyposis were at an increased
risk for the development of CRC. This same study also reported significant
morphological differences between the polyps associated with hyperplastic polyposis and
small HPs found in the general population. Hyman and colleagues (2004) found that 7 of
13 patients (54%) diagnosed with at least 30 HPs had developed CRC during the 5 years
after HP diagnosis . Recent studies have changed the impression that hyperplastic polyps
have no malignant potential and a new serrated neoplasia pathway has been proposed
based on the genetic and morphologic distinction ofHPs (Jass , 2001).
Serrated precursor lesions have been classified into two types, the hyperplastic
polyp and the advanced serrated polyp. The advanced serrated polyp type is further
classified into three types : traditional serrated adenomas , sessile serrated adenomas and
mixed polyps (Snover et al., 2005). Approximately 80-90% of all serrated polyps are
hyperplastic . The advanced serrated polyps are more likely to carry malignant potential
compared to HPs. Traditional serrated polyps are a form of adenomatous polyps that are
characterized by their serrated edge. These polyps are commonly found in the distal
colon and are associated with methylation of the MGMTgene as well as pathogenic
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variants in the BRAF or KRAS gene (Jass, 200 I) . Serrated sessile polyps are distinct from
traditional serrated polyps as these lesions are not pedunculated. The sessile serrated
adenomas can have T or L-shaped crypts in their architecture and have serration extended
to the base of these crypts. The mixed polyp is architecturall y a combination of the HP
and the traditional serrated adenoma (Jass , 2001) .
Mucosal polyps are benign outgrowths of the mucosa that are elevated by the
underlying sub-mucosa . These polyps are small in size (O.Scm) and can account for
approximately 18% of all resected small polyps (Waye et aI., 1988). These polyps do not
pose any risk for developing CRC and follow up screening is not needed (Markowitz &
Winawer ,1997).
Inflammatory polyps occur within the colon or rectum as a result of severe
inflammatory bowel disease. Regenerative repair or ulceration of the rectum or bowel
causes these polyps to form. Some inflammatory polyps are formed by residual colonic
mucosal tissue that projects into the lumen due to severe ulceration while others are
formed from regenerating mucosa and granulation tissue. These types of polyps are
usually associated with inflammation due to Crohn 's colitis or other condition s causing
underlying inflammation of the colon . They can cause abdominal pain or obstruction
(Markowitz & Winawer , 1997). Inflammatory bowel disease is associated with an
increased risk ofCRC, specifically in chronic ulcerati ve colitis . Patients with Crohn ' s
disease are also at a higher risk for developing CRC (Freeman , 2008) .
Hamartomatous polyps contain a mixture of normal tissues within the polyp and
have been identified in juvenile polyposis and Peutz-Jeghers syndrome (Markowit z &
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Winawer, 1997). Juvenile polyps are generally benign and do not pose a significant
malignant risk; however, in rare cases these polyps may show adenomatous or malignant
characteristics (Friedman et aI., 1982; Tung-Hua et aI., 1978).
Sub-mucosal polyps can be classified as lymphoid polyps . Lymphoid polyps are
commonly found in the rectum and are caused by the expansion of the lamina propria
associated with lymphocytic infiltration. These polyps are benign and are usually
asymptomatic occurring in individuals between the ages of20-60 years (Markowitz &
Winawer, 1997). Lipomas are usually found in the proximal colon incidentally during
colonoscopy. These asymptomatic, benign entities do not need to be removed and require
no follow-up surveillance. (Markowitz & Winawer, 1997) .
Efforts to prevent the onset of CRC now focus on screening individuals for
colorectal polyps that may develop into a malignant form . There is reasonable data that
show that CRC develops from normal mucosa, which then develops into benign
adenomas, and subsequently into carcinomas. There is also a great amount of evidence
that indicates that the resection of adenomatous polyps prevents CRC (Bond, 2000) .
Colorecta1 polyps can be diagnosed through barium radiography, endoscopic procedures
or virtual colonoscopy. Most polyps are removed from the colon during colonoscopy by
electrocautery techniques. Small polyps (> I em) should be removed and biopsied, to
indicate if follow-up is needed. Large sessile polyps «2 em) should be biopsied and a
follow-up colonoscopy should be completed in 3-6 months to confirm a complete
resection (Bond , 2000). Colonoscopy screening should be considered for the first degree
relatives of individuals that have had adenomatous polyps before the age of 60 years .
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CRC is one of the most curable cancers if detected in its early stages. To date, the
best way to manage CRC is through prevention. It is recommended that a fecal occult
blood test or fecal immunochemical test be conducted every two years for individual s
over the age of 50 (Canadian Cancer Society , 2011). Positive fecal tests should be
followed by a colonoscopy or double contrast barium enema and flexible sigmoidoscopy
for a definitive diagnosis. While screening procedures have been shown to benefit the
entire population (Bond , 2000) , such procedures are most beneficial to those at high risk
based on a family history of the disease and/or those with a known hereditary
predisposition .
1.5 Colorectal Can cer and GALNTl2
1.5.1 The Association between CRC and Chromosome 9q22
Several studies have identified a link between CRC risk and chromosome 9q22.
In 2003, Wiesner and colleague s genotyped 53 familial colorectal neoplasia kindreds and
conducted multipoint linkage analysi s to test for genetic linkage . The kindreds included
an affected sibling pair both diagnosed with either CRC or an adenoma with high grade
dysplasia , greater than I em in size, before the age of 65 years. Individuals having FAP
or LS were excluded from this study. Linkage was identified between the disease
phenotype and the chromosomal region 9q22.2-31 .2 (p= 0.00045) , which followed an
autosomal dominant mode of inheritance (Figure 1.2). A study by Skoglund et al. (2006)
also identified the chromosomal region 9q22 .32-31 .1 as a susceptibility locus for CRC
and adenomatous polyps . This study was a linkage analysis investigating a large Swedi sh
family who had an identified MSH2 mutation segregating through the family member s;
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Figure 1.2. Linkage of chromosome 9q22.2-31.2 to CRC phenotype . The x-axis depicts
chromosome 9 in cM and the y axis plots pP=-log lO(P value for linkage). Red line
represents the linkage for concordant twin pairs and the blue line represent s linkage using
all affected and unaffected siblings. Adapted from Wiesner et al. (2003) .
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however, this mutation was not present in eight individuals who had been either
diagnosed with CRC or adenomatous polyps. The analysis revea led linkage of CRC risk
to a region on chromosome 9 with a LaD score of2.4. These findings not only
supported those by Weisner et al. (2003) but also narrowed the region of9q22.2-31.2 to
9q22.32 -31.1, limiting it to 7.9 eM.
An additional study was also conducted in 2006 by Kemp and colleag ues who
genotype d 16 markers within the suggeste d susceptibility region of chromosome 9q22.2-
31.3, as defined by Weise r et al. (2003). Investigating 57 colorectal cancer families from
the United Kingdom, excluding those with known Mendelian syndromes, confirme d
linkage to the region chromosome 9q22.32 -31.1 using parametric (Heteroge neity
Logarit hm of Odds (HLOD) = 1.23) and nonparametric linkage (NPL= 1.21) analyses .
This linkage was found in 20% of the hereditary CRC families investigated. Subsequent
analyses using more stringent thresho lds, narrowed the region of susceptibility to just
- 1.7 eM (NPL>2.4, p= 0.007).
A validation study was conducted in 20 I0 by Gray-McQuire and colleagues ,
which further confirmed the linkage of CRC to a susceptibility locus on chromosome
9q22. This region was fine-mapped using single nucleotide polymorph isms (SNPs) and
moving window assoc iation analyses in 256 sibling colon cancer kindreds . A five-SNP
haplotype was shown to be linked to the disease phenotype which was also in strong
disequ ilibrium with another haplotype that lies in close proximity to GALNT12, which is
located at chromosome 9q22.33. GALNT 12 encodes a glycosy lation enzyme, UDP-N-
acety l-alpha-D-ga lactosa mine: polypeptide N-acety lgalactosami nyltransferase 12
(GALNTl2).
1.5.2 GALNT12: A Putative CRC gene
A study by Guda and colleagues (2009) identified a novel gene association with
colon cancer. Somatic and gennline variants were identified in the GALNT12 gene in
CRC cases. It was found that GALNT12 deleterious variants inactivate normal
functioning of the GALNT enzyme in initiating mucin type O-linked glycosylation. Guda
and colleagues (2009) sequenced 30 microsatellite stable colon cancer cell lines and
found 2 somatic variants, c.1023A >C, p.Glu341Asp and c.1436G >T, p.Cys479Phe,
which were not found in the normal colon tissue. Through functional testing , it was found
that the somatic mutations almost completely inactivated GALNTl2 enzymatic activity
«3% of wild-type).
Guda and colleagues (2009) then analyzed the complete coding sequence of
GALNT12 in gennline DNA samples from 272 colon cancer patients . Seven sequence
variants were found among the colon cancer patients which were not found within the
control group (192 individuals). Functional testing revealed that 6 of the 7 variant s
essentially knocked out enzymatic activity while the seventh variant reduced activity to
37% (Figure 1.3). The authors hypothesize that inactivity of this protein could increase
the number of improperly glycosylated or unglyco sylated proteins in colon cancer
tumours. This study provides support for the notion that GALNT12 pathogenic variant s
may contribute to the etiology of CRC.
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Cases C o ntro ls
Figure 1.3. Characterization of GALNTI2 variants. Upper: specific enzymatic activity
(norma lized to wild-type) associa ted with variants found in germ line DNA within CRC
cases and controls. Lower: Protein express ion associated with each variant. Adapted from
Gudaetal. (2009).
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1.5.3 GALNT12 Function
GALNTl2 has ten coding exons and is located on chromosome 9q22.33 (Figure
1.4).GALNT12 encodes the enzyme N-acetylgalactosaminyltransferase type 12
(GALNTl2) which belongs to a superfamily of N-acetylgalactosaminyltransferases
(ppGaINac-Ts) (Hashimoto et aI., 2011) . The family ofppGaNTases are respons ible
for the transfer of a monosaccharide N-acetylgalactosamine (GaINAc) from UDP-
GalNAC sugar donor to the hydroxyl group of a serine or threonine of the mucin prote in
(Hashimoto et aI., 20 II). This enzymatic monosaccharide transfer takes place in the
Golgi and is considered the first step in mucin O-linked glycosylation (Ten Hagen et aI.,
2003) . While the tertiary structure of the ppGalNac -Ts has not yet been determined , it
has been suggested that all GALNT enzymes share a common p-pleated sheet with u-
helices on either end (Hagen et aI., 1999). There are approximately 24 unique human
isoforms within the GALNT family which are tissue specific and GALNT12 is known to
be highly expressed in the human colon (Ten Hagen et aI., 2003; Guo et a\., 2002) .
Mucin glycoproteins are ubiquitously distributed throughout epithelial cell
surfaces and are important for cell adhesion , proliferation , differentiation, immunity ,
aging and cancer development (Hashimoto et a\., 2011) . The colonic epithelium , along
with other epithelial surfaces in the body, is protected by a mucus layer that consi sts
mainly of mucin glycoproteins (Byrd & Bresalier , 2004) . Abberant glycosylation in
mucin proteins is a hallmark feature of colonic neoplasia (Brockhaus en, 1999). The
proper glycosylation of mucin proteins plays an important role in the preferred
backbone structure of the protein and influences the capability of the subsequent
glycosylation events (Hashimoto et a\., 2011) . The altered structure ofmucins through
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Figure 1.4. A: Coding nucleotide sequence of GALNTl2. Nucleo tide positio ns are
numbered starting from the first nucleotide of the initiation codon. The predicted amino
acid sequence is provided below. Arrows indicate the junction between introns and
exons. The triangle identifies a truncated position. Adapted from Guo et al. (2002) . B:
GALNT12 location on chromosome 9q22.33. Retrieved from
http://www .genecards.org/cgi-bin/carddi sp.pl?gene=GALNT I2.
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abberant glycosylation is associated with increased growth and survival of cells as well
as an increased ability of cells to invade and metastasize (Brockhaus en, 1999).
Additionally , the proper structure of mucin proteins are important for interactions of
potential ligands with cell surface receptors, which playa major role in immunity . Guda
and colleagues (2009) found that there were increased levels ofunglycosylated MUCI
proteins in 3 colon tumours compared to normal colon mucosa; although the expression
ofMUCI proteins in the colon tumour was normal. Studies are ongoing to identify 0-
linked carbohydrate structures of mucins in CRC, which may be useful as diagno stic
and prognostic tools as well as targets for cancer vaccines (Byrd & Bresalier, 2004) .
Molecu lar cloning and characterization of GALNT12 was carried out by Guo et al.
(2002) . They conducted a Quantitative real time PCR assay which revealed that
GALNT12 was mainly expressed in the tissues of digestive organs, including the
stomach, small intestine and colon (See Figure 1.5).
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Figure 1.5. Expression of GALNTl2 in different tissues determined by Quantitative real
time peR. GALNTl2 is expressed the most in the digestive tissues including the stomach ,
small intestine and colon . Adapted from Guo et al. (2002).
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Chapter 2
2.0 Investigating the Genetic Component of Colorectal
Cancer in Newfoundland: A Clinical and Population-
Based Study
2.1 Colorectal Cancer and the Newfoundland Population
The province of Newfoundland and Labrador (NL) has the highest incidence rates
ofCRC nationwide (Canadian Cancer Statistics, 2011) , with 67 individuals per 100,000
affected compared to the national average of 49 individuals affected per 100,000
(Canadian Partnership Against Cancer , 2009) . The mortality rate associated with CRC in
Newfoundland is twice that in British Columbia, reflecting the high incidence rates in the
NL population (Canadian Cancer Society, 2011).
The population structure ofNL is unique in that it consists of numerous founder
populations. This is due to the small number of early settlers to the province in the mid -
1700s. The first settlers were mostly Roman Catholics from Ireland or Protestants from
England (Mannion , 1977). The island was initially populated with approximately 20,000-
30,000 immigrants who settled along the coastline establishing out-port fishing
communities. From 1760 to present , the population grew to over 500,000 due to natural
expansion with over 50% of the population still living in rural communities of 2,500
people or less (Statistics Canada, 20 I0). The geographic isolation between communities
and the religious pressures within each community produced severa l pockets of
genetically isolated populations , some of which have been known to have founder
mutations (Rahman et a\., 2003) . The founder effect occurs when a small group from a
larger populat ion forms a new colony . Any mutations that were present within the
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individuals that branched off from the larger population will likely become established in
the new population after several generations and these mutations will be present at a
higher frequency in the smaller population compared to the original population. Founder
mutations have been identified in a number of Newfoundland communities for several
disorders including; Bardet-Biedl syndrome (young et aI., 1999), Hemophilia A (Xie et
aI., 2002) Multiple Endocrine Neoplasia type I (Olufemi et aI., 1998) and CRC (Spirio et
aI., 1999). For example, a deleterious variant that affects the 3' splice acceptor site of
MSH2, c.942+3A >T identified in Family C (an extensive hereditary CRC family), was
also identified in 12 other families, which were all from the same geographical location
(Green et aI., 2002). Two large deletions of the MSH2 gene were also identified; a
deletion of exon 8 (c.1277-?_1386 +?del, p.Lys427 _Gln462 >GlyfsX4) in 10 families and
a deletion ofexons 4 to 16 (c.646-?_2802+?del) in one very large family. Given its
unique genetic structure, the Newfoundland population is an ideal resource for studying
genetic diseases and identifying associated novel mutations.
In order to better understand the epidemiological, genetic and environmental
factors associated with the high incidence ofCRC in the Newfoundland population , the
Newfoundland Colorectal Cancer Registry (NFCCR) was created . Individuals diagnosed
with CRC from 1999 to 2003 were approached to be included in the registry (for more
details see Materials and Methods-study population). This population-based cohort was
assessed for familial risk ofCRC based on FAP criteria , AC-I , AC-II , and Bethesda
criteria outlined by Green et al. (2007) (see Table 2.1). It was found that 4.6% of this
population met the high risk AC-II or FAP criteria ; 43% met the intermediate risk
30
Tabl e 2.1 CRC Risk Assessment
Family Risk Category Criteria Comments
High-risk FAP Known FAP or AFAP Mutation detected in APe gene or,
clinical diagnosis ofFAP or AFAP in
proband's family
High-risk HI Family meets AC-I
High-risk H2 Family meets AC-II
Intermediate 81-85 Proband meets
Risk revised 8 ethesda
guidelines
Low-risk Neither high or
intermediate risk
Proband is not necessarily in the AC-I
triad.
Tumours recognized by the
Amsterdam II
criteria:colorectal,endometrial,small
bowel,ureter,renalpelvis
Tumours:co lorectal,e ndometria l,
stomach,ovarian, pancreas , ureterand
renal pelvis, small bowel,b iliary tract,
brain(glioblastoma),sebaceouscell
adenomas and keratoacanthomas
Adapted from Green ct al. (2007).
Bethesda criteria and 30% of all the patients had a first- degree relative diagnosed with
CRC (Green et aI., 2007).When indicators of familial risk were compared to 13 other
population-based studies worldwide, these indicators were significantly higher for the
Newfoundland population (Green et aI., 2007) .
Woods et al. (2005) investigated tumours from high risk CRC families for
deficiencies in MLHI , MSH2 , and MSH6 proteins and DNA microsatellite instability.
They found that 50% of the population-based families which fulfilled the high risk AC-
IIII did not have MMR deficiencies. In addition, 76% of the high risk AC-IIII families
referred to the Provincial Medical Genetics Program (PMGP) to did not have causal
variants identified in the tested MMR genes.
Investigations carried out using the NFCCR have indicated that over 50% of the
families meet the high or intermediate risk criteria (Green et aI., 2007) , suggesting that
there is a high incidence of familial CRC in the Newfoundland population. Studies have
also indicated that the high rate of familial CRC may be attributed to novel unidentified
genetic factors (Woods et aI., 2005; Woods et aI., 2010). Considering the high incidence
of unexplained familial CRC in the province of Newfoundland and several studies
supporting the involvement of GALTN12 in CRC, we investigated the involvement of
GALNTI2 variants in the Newfoundland CRC population .
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The purpose of this study was to investigate the involvement ofGALNTJ2 causal
variants in hereditary CRC families from Newfoundland. By better understanding the
relationship between GALNTJ 2 causal variants and the onset of CRC, treatment and
screening programs for this disease can become more specific and effective . There were
two main objectives of this study.
1) To screen for variants in GALNTJ 2 in hereditary CRC families by performing
direct DNA Sanger sequencing in 129 probands referred to the Provincial Medical
Genetics Program .
2) To determine the causality of GALNTJ 2 variants found in probands by
performing segregation studies in family members and also screening population-
based CRC cases and controls .
The impact of these variants was assessed by sequencing three different groups ; (1)
affected and unaffected family members of the probands from the clinical cohort; (2) a
replication group from the NFCCR to determine the CRC population-based frequency of
the variants, and (3) a healthy control group to determine the population based frequency
of the identified variants . Bioinformatic tools and functional test results by Guda et al.
(2009) were also used to help determine the impact of variants on protein function .
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Chapter 3
3.0 Materials and Methods
3.1 Study Population
CRC patients included in the study came from two separate cohorts : clinic-based
and population-based registries . The first cohort included 129 individuals diagnosed with
CRC, who were referred to the Provincial Medical Genetics Program by their physician .
Venous blood was drawn from the proband and family members of each family and
whole genomic DNA was extracted. The second cohort included 48 I individuals who
were ascertained through the Newfoundland Colorectal Cancer Registry (NFCCR) that
had not previously been referred to the Provincial Medical Genetics Program. Subjects in
the NFCCR were recruited during the period of 1999-2003 and were diagnosed with
CRC before the age of75 in Newfoundland and Labrador. DNA samples, paraffin-
embedded tumour samples, family history and access to medical records were obtained
from each consenting individual. Control DNA samples were obtained from volunteers
by random digit dialing. These subjects had no personal or family history of epithelial
cancer, they provided a blood sample, provided family history and consented to be
included in research studies . This project was approved by the Research Ethics Board of
Memorial University of Newfoundland.
3.2 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was conducted to amplify all coding sequence
and flanking intronic sequences of GALNT12. Forward and reverse primer sequences
were obtained from Guda et al. (2009). Primers were manufactured by Eurofins MWG
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Operon (Hunts ville, Alabama). Stock primers were diluted to a final concentration of 100
ng/ul (see appendix C for primer sequences). Positive control s were used to obtain
optimal conditions for the PCR reaction using control DNA at 100 ng/ul,
Approximately 1.0 IIIof genomic DNA from a stock concentration of 100 ng/ul
was added to a 96-well 0.2 ml PCR reaction plate . For reactions amplifying exons 2-10 a
cocktail containing 10.75 IIIof deionized water, 1.5 IIIof lOX PCR react ion Buffer
(MgCb), 0.3 III of 100 ng/pl dNTPs (deox yribonucleotide triphosphate), 0.5 IIIof 10 lIM
forward primer , 0.5 IIIof 10 lIM reverse primer , 0.75 IIIof 50 mM MgCI and 0.2 IIIof
Platinum Taq Polymerase was prepared and added to the 96-well 0.2 ml PCR reaction
plate (materials for the cocktail were obtained from Life Technologies, Burlington, ON) .
Negative controls were tested using 1.0 IIIof deioni zed water instead of DNA. The plate
was then centrifuged and incubated in a Biometra Thermocycler (Biometra GmbH ,
Goettingen , Germany) or EppendorfThermocycler (Eppndorf, Hamburg , Germany ). The
thermocycler condition s were as follows : an initial cycle of denaturation for 5 min at 95.0
"C. This was followed by 30 s of denaturation at 95 °C, annealing of primers for 30 s at
60.0 °C and extension of DNA strands for 30 s at 72.0 °c for 25 cycles . This was
followed by extension of strands for 7 min at 72.0 °C and then a hold at 4 "C.
Due to difficulty in amplifying exons 1 and 10d, a different protocol was used. A
cocktail containing 22 U/ml Thermococcus species KOD thermostable polymerase, anti-
KOD antibodies , 66 mM Tris-S04 (pH 8.4), 30.8 mM (NH4hS04, II mM KCI, 1.1 mM
MgS04, 330 lIM dNTPs , Accul'rime" proteins , stabilizers 1.0 IIIof 10 lIM forward
primer, 1.0 IIIof 10 lIM reverse primer .
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For exon I thermocycler conditions were as follows: an initial cycle of
denaturation for 3 min at 95.0 °c , followed by 30 s of denaturation at 95 °C, annealing of
primers for 30 s at 55.0 "C and extension of strands for I min at 72.0 "C for 35 cycles .
This was followed by extension for 10 min at 72.0 °C and then a hold at 4 "C. For exon
10d the thermocycler conditions were as follows: an initial cycle of denaturation for 2
min at 95.0°C. This was followed by 20 s of denaturation at 94 °C, annealing of primers
for 45 s at 60.0 °C and extension for 45 sat 72.0 "C for 14 cycles. This was followed by
20 s of denaturation at 94 °C, annealing of primers for 45 s at 50.0 °C and extension for
30 s at 72.0°C for 32 cycles completed with a hold at 4 °C.
To confirm that the PCR was producing the appropriate amplicon, the products
were added to a 2% agarose gel which contained Ig of Ultrapure Agarose (Life
Technologies, Burlington , ON), 50 ml ofTris/Borate/EDTA (TBE) buffer and 3.8 ul of
SYBR®Safe (Life Technologies, Burlington, ON) . Approximately 3.0 ul ofPCR product
was mixed with 3.0 ul of dye and 1.0 ul of DNA ladder was mixed with 3.0 ul of dye .
These mixtures were added to the agarose gel. The gel was then subjected to
electrophoresis (120 V for 25 min). An image of the gel was then captured using a Kodak
UV imager (Kodak, Rochester, New York).
3.3 Polymerase Chain Reaction Purification
PCR products were purified using Exo Nuclease I (ExoI) and Shrimp Alkaline
Phosphatase (SAP) . ExoI was used to digest any excess primer left in the PCR product.
SAP was used to dephosphorylate free deoxynucleotide triphoshates (dNTP's) from the
product. A cocktail containing 7.5 ul of deionized water, 0.5 ul of ExoI (10 VI ul) and
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0.5 IIIof SAP (I VI Ill) was added to a 96 well 0.2 ml PCR plate. Approximately 8.0 III
ofPCR product was added to the mixture and incubated at 37°C for 30 min followed by a
15 min incubation at 80°C to inactivate the enzymes.
3.4 Sequencing Reaction
Bi-directional sequencing was performed for each of the coding regions and the
exonlintron boundaries of the GALNTl2 gene for the clinical cohort . Bidirectional
sequencing was carried out in only exons 4 and 6 for the population-based cohort as
variants identified in the clinic-based cohort occurred in these exons. A cocktail
containing 2.0 IIIof BigDye Terminator v3.1 Cycle Sequencing 5X Buffer, 0.5 IIIof
BigDye Terminator v3.1 Cycle Sequencing Mix (Applied Biosystems, Foster City,
California), 0.67 IIIof primer (1.6 pmol/ul), and 14.83 IIIof deionized water was
prepared. Approximately 18.0 IIIof the cocktail and 4.0 IIIof purified PCR product was
added to a 96 well 0.2 ml PCR plate. The plate was then incubated at 96°C for I min
followed by 25 cycles of 96 °C for lOs , 50°C for 5 sand 60 °C for 4 min.
3.5 Sequencing Reaction Purification
The sequencing reaction was then stopped by adding 5 III 1.25mM
ethylenediaminetetraacetic acid (EDTA) followed by 65 IIIof95% ethanol solution . The
plate was vortexed and placed in the dark overnight to allow the sequencing product to
precipitate out of solution. The plate was then centrifuged for 45 min at 3000g. The plate
was then inverted and centrifuged for 30 s at 350 rpm to allow the ethanol to decant. The
samples were washed with 150 IIIof70% ethanol solution and the plate was centrifuged
at 3000g for 15 min. The plate was inverted again and placed in the centrifuge at 350 rpm
37
for 30 s to remove any excess supernatant. Samples were resuspended in 18 IIIofHiDi
formam ide by vortexing. The plate was then centrifuged and the sequencing product was
denatured by incubation at 95 °C for 2 min. The caps were then replaced with a Septa
seal and placed in the ABI Prism 3130 or 3730 Automated Genetic Analyzer for
automated sequencing (Applied Biosystems, Foster City, California).
3.6 Sequencing Analysis
Data obtained from the automated genetic analyzer was examined for quality
control using Sequencing Analysis v5.2 software and also by manual analysis. The target
quality versus fair and poor qualities are shown in Figure 3.1. Sequence of good quality
shows high sequenced peaks with minimal background peaks. As the quality moves to
fair and poor there is an increase of background noise that is less distinguishable from the
main sequence peaks , increasing the difficulty of making accurate nucleotide calls. Fair
and poor quality sample sequences were only used in conjunction with a good quality
sequence for that sample in the opposite direction.
The sequence data from the genetic analyzer was investigated for variants by
comparing it to a reference sequence obtained from the Ensembl database
(http ://ensembl.org /index.html) . Sequencher v4.9 software was used to align the sample
sequence with the reference sequence to identify variants . Only variations that occurred
in both the forward and reverse sequences were considered to be genuine. Potential
pathogenic variants were confirmed by repeating the reaction using a separate aliquot of
DNA from the same individual for quality control purposes
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Figure 3.1 Manual examination of data quality . Adapted from Kamel (2010).
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3.7 Segregation Analysis
SImplified rapid Segregation Analysis (SISA) was used to assess the probab ility
of co-segregation by chance of GALNTl2 variants in families that showed segregation.
(Me ller et aI., 20 II ). SISA assesses penetranc e and express ion of genetic variants that
have unknown pathogenic significance based on a number of assumptions; ( I) the variant
is introduced only once into that family; (2) the probabili ty of recomb ination is zero; and
(3) a family member that occur s between two member s that are known to be carrier s of
the variant is considered to be an obligate carrier. The pr obability ofcoseg regation by
chance is calculated by (1/2)", where n equals the number of informative meiosis
(number of people included in the carrier set minus one). Expression (fraction of
individuals that have a specific phenotype among all affected individuals) is simply
calcul ated as the number of persons with one (or some) of the phenotypi c characteristics
considered to be associated with affected status, divided by the total number of
individuals who are affected. Penetrance is calculated by the number of affected carriers
divided by the number of carri ers. Calculating a low probability for co-segregation by
chance and high penetrance may indicate that the variant of unknown significance is
causing the phenotype. Calculat ing a high probabilit y of cosegregation by chance and a
low penetrance may indicat e that the variant is not associated with the observed
phenotype. For a more detailed explanation, see Mell er et aI. (2011).
3.8 Determining Pathogenicity ofldentified Variants
The population frequency of all variants, identified though sequencing , within the
exons and exonlintron boundarie s, was determ ined using the Ensembl database. Ensembl
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database is linked to the global SNP database, dbSNP
(http ://www.ncbi.nlm.nih.gov/projects /SNP/) , which reports human population
frequencies of these variants. Population frequencies were noted (when available) for all
variants that were previously identified in dbSNP based on the 1000 Genomes Project
(http ://www.l000genomes.org/).
All variants with a population frequency of less than I% were investigated within
the family for segregation patterns with the CRC phenotype . All non-synonymous
variants affecting amino acid sequence were investigated for pathogenicity using
bioinformatic software including PolyPhen (Adzhubei et aI., 2010;
http://genetics.bwh .harvard .edu/pph2D, SIFT (Ng & Henikoff, 2001; http://sift.jcvi .orgD
and Panther (Thomas & Kejariwal , 2004; http ://www.pantherdb.orgD.Align GVGD was
also used to predict pathogenicity of variants identified in this study. Align GVGD is an
expansion of the Grantham chemical difference matrix (Grantham, 1974) which takes
into account the biophysical characteristics of amino acids and also uses protein multiple
sequences alignments to estimate if protein variants are deleterious or neutral (Tavtigan et
aI., 2005 ; Mathe et aI., 2006). For variants previously reported by Guda and colleagues
(2009), enzymatic function was based on previously reported functional testing . The
Newfoundland population based frequency of putatively pathogenic variants was
investigated by sequencing exons of age-matched controls.
3.9 Statistical Analysis
Statistical analysis was carried out to analyze differences between the frequencies
of potential pathogenic variants in the case and control group . Fisher 's exact test was
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employed using QuickCal s online software
(httn ://www .graphpad .com/quickcalcs/index .cfm).
3.10 Criteria for Affected Familv Members
While al1the proband s included in both cohort s have been diagnosed with at least
a single case of CRC, relatives of the proband included in the disclosed family history
were considered affected if they had been diagno sed with CRC or at least one
adenomatou s polyp . Adenomatou s polyp s are considered a precursor to CRC as these
polyps often progre ss into a malignant form. It is also important to note that , due to
increased screening in individuals belonging to hereditary CRC families , affected family
members are more likely to have adenomatou s polyps removed before they develop into
cancer. Therefore, it is important to include individual s with adenomatous polyps in the
affected phenotype.
Chapter 4
4.0 Results
4.1 Clinically Referred Families
There were 129 probands from families referred to the PMGP included in this
study. Approximately 68% of the cohort met the Bethesda criteria, 21% met the
Amsterdam IIII criteria and II% did not meet either criteria and were considered low
risk. Of the 129 probands , DNA from 120 cases was successfully sequenced in all
coding regions and intron/exon boundaries of GALNT12. Four individuals were found to
harbour putatively deleterious variants . A number of putatively non-pathogenic variants
were also identified . All variants found within this cohort are reported in Table 4.1.
4.1.1 Putatively Pathog enic Variants
Two potential pathogenic variants were identified in four different probands .
Three cases were found to harbour the c.907G>A (p.Asp303Asn) variant , which was
previously reported by Guda and colleagues (2009) . A novel variant, c.1187A>G
(p.Tyr396Cys) was identified in one individual. A summary of the putatively pathogenic
variants identified in GALNT12 is shown in Table 4.2.
The variant, c.907G >A (p.Asp303Asn), was investigated using bioinforrnatic
tools such as PolyPhen, SIFT and Panther. PolyPhen predicts this variant to be "probably
damaging" with a score of 0.999 (a score of 0.0 being neutral and a score of 1.0
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Table 4.1 Gennline variants in GALNTJ2 identified in clinically based probands.
Frequency
Variant Exon Cases Controls Population '
c.136G >A (p.Gly46Arg) 0.008 ND ND
(rs10987768)
c.356A>T (p.GluI19Val) 0.083 ND 0.018
(rsI0987769)
c.78IG>A (p.Asp26IAsn) 0.016 0.012 0.008
(rs41306504)
c.907G >A (p.Asp303Asn) 0.025 0.00 ND
c.1187A >G (p.Tyr396Cys) 0.008 0.00 ND
c.1497C >T (p. =) 0.008 ND 0.026
(rs35632007)
c.1707G >C (p. =) 10 0.046 ND 0.157
(rs2273846)
c.1734G >A (p. =) 10 0.016 ND ND
c.*17IA>G 10 0.033 ND 0.157
(rs2773847)
c.*42IG>A 10 0.083 ND 0.064
(rs2273848)
I Daia sourced from dbSNP [http ://www .ncbi.nlm.nih.gov/project s/SNPI] via Ensembl
[http ://www .ensembl.org) ; ND: not determined
Table 4.2 Putati vely pathogeni c GALN T12 variants in clin icall y ba sed probands with
clin ical information,
Study # Variant Proband Age of Location of MSI1 IHC2 Family'
Diagnosis Cancer Testing Testing Risk
1117 c.9 07G>A, 72 Rectum MSS intact B24
p.Asp303Asn
20444 c.907G>A 35 Rectum ND ND B45
p.Asp303Asn
20 896 c.907G>A 71 Transverse MSS intact B25
p.Asp303Asn Colon
1728 c.1187A>G 21 Cecum MSS intact Bl
p .Tyr396Cys
IMSS: microsatellite stable; ND: not determin ed. 2IHC testing was conducted using the MLHI , MSH2 and
MSH6 prote ins. 3Bethesda criteria: I, CRC diagnosis less than 50 years of age; 2, synchronous or
metachronous tumours (colorectal or HNPCC); 4, one ISl degree relative with HNPCC related tumour
under 50 years of age; 5, two ISl or 2nd degree relatives with HNPCC related tumours at any age. Family
risk criteria are outline in Green eta l. (2007).
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representing deleterious changes). SIFT predicts this change to be "not tolerated" and
Panther reported a subPSEC score of -4.33 and a Pdc)ctcriousscore of 0.791 for the
p.Asp303Asn change. The subPSEC score in Panther represents the "negative logarithm
of the probability ratio of the wild type (WT) and mutant amino acids at a particular
position" (Brunham et aI., 2005). These scores are continuous values that range from 0
(mostly likely benign) to -10 (most likely pathogenic). The Pdc)ctcrious is the probability of
functional impairment of a specific amino acid change (Brunham et aI., 2005). See Table
4.3 for a summary of the bioinformatic data obtained . The Grantham chemical difference
matrix was also employed to estimate the pathogenicity of this variant, c.907G >A (see
Materials and Methods section 3.8). The Align GVGD classification for this amino acid
change, p.Asp303Asn, is Cl5 (Table 4.3). Scores for amino acid changes range from CO,
less likely to interfere with the function of the protein , to C65, most likely to interfere
with protein function .
The variant , c.1187A>G (p.Tyr396Cys), was not identified by Guda et al. (2009)
and therefore functional testing has not been previously conducted . We conducted
bioinformatic analysis on this variant and it was predicted to be pathogenic (PolyPhen,
SIFT and Panther) . PolyPhen predicted this variant as "probably damaging" with a score
of 0.999. SIFT predicts this change as "tolerated" and Panther calculates a subPSEC
score of -9.28 and a PdclctcriousofO .998 (Table 4.3). The Align GVGD classification for
this amino acid change, p.Tyr396Cys, is C65 (Table 4.3).
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Table 4.3 Bioinfonnatic analysis of non sy nony mo us GALNT12 variants identifi ed in c lin ic al probands .
Bioinfonnati c Tools
Variant Exon SIFT I Polyl'herr' Panthe~
(Prediction, Pddetedous) (subPSEC, Pdd,,,,;ous)
c.136G>A (p .Gly46Arg) I T D Unknown -2 .99 ,0.498
c.356A>T (p .GluI19Val) I TD PsD ,0.788 -4 .62, 0 .86 5
c .78IG>A (p.Asp26IAsn) 4 TD PrD ,0.997 -3 .3 5, 0 .5 86
c.907G>A (p .Asp303Asn) 4 NT PrD ,0.999 -9 .28, 0 .9 98
c .1190A>G (p.Tyr396Cys) 6 NT PrD ,0.999 -4.33,0.791
Ali gn
GVGD 4
C65
C65
CI5
CI5
C65
ITO: tolerated; NT: not tolerated. 2psD: possibly damaging; PrO: probably damaging. 3 subPSEC: the "negative logarithm of the probability ratio of the
wild type and mutant amino acids at a particular position" (Brunham et aI., 2005). These scores are continuous values that range from 0 (mostly likely
benign) to -10 (most likely pathogenic). ' Classifications are listed from most likely to interfere with protein function to least likely; C65 (most likely),
C55, C45, C35, C25, C15, CO(less likely).
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The variant, c.907G >A (p.Asp303Asn) , was identified in a Newfoundland family
of European descent (family 20444) . This family fulfills the Revised Bethesda criteria :
however , it seems likely that this family may have met the high-risk Amsterdam I criteria
if the youngest generation had not been receiving high-risk colonoscopy screening
(Figure 4.1) . The point mutation , c.907G>A (p.Asp303Asn) , causes an amino acid
change from aspartic acid to asparagine (p.Asp303Asn) . This variant has been previously
reported by Guda and colleagues (2009) to reduce enzymatic activity to 37% ofWT
function . The female proband (PID 6) was diagnosed with cancer of the rectum at age 35
and skin cancer at age 82. All four children of the proband were negative for the
c.907G>A variant. The proband ' s sister (PID 4) also carried the point mutation and was
diagnose d with cervica l cancer at age 37 and colon cancer at age 61. Six of her eight
children also have the variant; no DNA was available for a ninth child . Four of the six
carriers have presented with colonic polyps (PID 7, 8,10,12) while two of the carriers
did not have polyps. Two other siblings were non-carriers and have not presented with
polyps or CRC (PID 14, 15). Of the four carriers that have been diagnosed with polyps ,
two had adenomas (PID 7,12), one had hyperplastic polyps (PID 8) and the other
individual's polyp type is unknown (PID 10). One individual who is negative for the
variant had a small cecal polyp which was not recovered for patho logical analysi s (PID
13; Tab le 4.4) .
Unfortunately, adequate size tumour tissue was not avai lable from the proband or
her sister for microsatellite instabil ity and immunohistochemistry (IHC) analysis. The
MLH I. MSH2 and MSH6 genes were sequenced in the proband and her sister. No
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e = CRC
+ =c.907A>G
- = wild type
~ = polyps
Hjp
Family 20444
Hyp AiJDI
Hjp
Figure 4.1 Partial pedigree for family 20444 with the segregating c.907G>A,
p.Asp303Asp GALNT12 variant. Arrow indicates proband . Hyp: hyperplastic polyp ; Adn :
adenomatous polyp; Vim: polyp type unknown.
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Ta ble 4.4 Medical history of clinical family members with probands harbouring a
putatively pathogenic variant in GALNT12 .
Study # PlD l Cancer Diagnosis' Polyp Data 3
20444 Cervical Cancer 37yrs NA
CRC (descending) 61 yrs.
20444 CRC (rectum) 35 yrs. NA
Skincancer82yrs.
20444 NA 2TAsat43yrs.
Mull. TAs at 44/45 yrs.
I TAat54yrs.
2 TAsat 60 yrs.
20444 NA I HYPat60yrs.
20444 10 NA Small polyps
(age unknown , type
unknown) .
20444 II NA 3 HYPs at 37 yrs.
20444 12 NA 7TAsat51 yrs.
ITA and I HYP at 53
yrs.
20444 13 NA I small cecal polyp at47
yrs.
Normalcolonoscopyat
49yrs.
20896 3 CRCs; I at 72 yrs. and 2 Mult . TAs and HYPS
at 79 yrs. between 73 and 81 yrs.
20896 2CRCs; I at 77 yrs. and I I pedunculated polyp
at83yrs. and2 sessile polyps (age
unknown)
20896 UpperGI "Ca of stomach" NA
in "late 70s"
Mass in transverse colon
at82yrs.
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20896 II NA I TA with seve re
dysplasia at 53 yrs.
Several sma ll polyps and
2 HYPs (age unknown) .
20896 12 Duke ' s A rectal carcinoma 2TAsat35yrs.
at57 yrs. I TAat60yrs.
(mo derate dysplasia)
3TAsat61 yrs.
3TAsat62yrs.
20896 13 NA Norma l colonoscopy at
47 yrs .
2 HYP s at 54yrs.
20896 14 NA 2 large TAs on stalks
with moderate dysplasia
at 45 yrs .
20896 18 Duke ' s C carcinoma at57 TA at 57 yrs.
yrs.(inpreexistingTA)
1117 12 CRC at 47 yrs. NA
1117 18 2 CRCs at 72 yrs . NA
Ca skin at 74 yrs .
1117 19 CRC at 67 yrs . NA
1117 23 CRC at 62 yrs . NA
1117 Castomac h at68 yrs . NA
1117 CRC in situ at 55 yrs . NA
1117 CRCat70yrs. NA
1117 CRCat7 0yrs. NA
1117 15 CRCat2 1 yrs.(Ca NA
appendix?)
I PID: personal identification number; 2NA: not applicab le, CRC: colorectal cancer, TA: tubular adenoma,
HYP: hyperp lasticpolyp
51
deleterious variants were identified in these MMR genes . The MUTYHgene was not
investigated in this proband .
A second Newfoundland family was identified with the same c.907G >A
(p.Asp303Asn) variant. The male proband (PID 3) of family 20896 presented with
multiple adenomatous and hyperplastic polyps , was diagnosed with a colon tumour at age
72, and two synchronous colon tumours at age 79 (Figure 4.2; Table 4.5) . The proband
had six children, three of whom took part in the study (PID 12,13,14). One daughter
(PID 12) who was found to have the variant , was diagnosed with rectal cancer at age 57,
and presented with three adenomas at 61 years and an additional three adenomas at 63
years . A second daughter (PID 14) was also found to carry the c.907G >A variant and she
presented with two colonic adenomas with moderate dysplasia at age 45. A third daughter
(PID 13) was found to be WT for the variant and presented with two hyperplastic polyps
at 54 years . The proband had twin sisters who were both diagnosed with cancer. One twin
sister (PID 7) was diagnosed with cancer of the cecum at age 77 years and a second colon
cancer at age 83. This woman had a son (PID 18) who was diagnosed with colon cancer
at age 57, and was found to be WT for the c.907G >A (p.Asp303Asn) variant. The other
twin sister (PID 8) had cancer of the stomach (late 70s) and also presented with a mass in
her transverse colon at 82 years . This mass was not surgically removed nor was it
biopsied. This family fulfills the Revised Bethesda Criteria and may have met the high-
risk Amsterdam criteria if they were not undergoing "high-risk" screening for the disease.
The proband of this family does not harbour any disease causing variants in the MUTYH
gene and the proband's tumour sample is microsatellite stable (MSS) and intact for mc
ofMMR proteins (Woods et aI., 2010) . The pedigree is presented in Figure 4.2.
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e = CRC
+ =c.907A>G
- = wild type
[2]= polyp
u
CRC (S1)
A4D/ Adn H)'P
H)p
Family 20896
17
~S1)
Figure 4.2 Partial pedigree for family 20896 with the partially segregating c.907G>A,
p. Asp303Asn GALNTJ2 variant. Arrow indicates proband. Hyp: hyperplastic polyp ;
Adn: adenomatous polyp; Ukn: polyp type unknown.
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The medical histories for family 20444 and 29896 are presented in Table 4.4 .
SISA was conducted on families 20444 and 20896 to determine the probability of
co-segregation by chance of the c.907G>A variant with CRC and/or adenomatous polyps .
The probability of co-segregation of c.907G >A with the disease phenotype by chance , for
both pedigrees combined , was 1.56%. Family 20444 had a 6.25% probability of co-
segregation by chance and family 20896 had a 25% probability of co-segregation by
chance.
A third proband harboring the c.907G >A (p.Asp303Asn) variant is from family
1117 and fulfills the Revised Bethesda Criteria (PID 18; Figure 4.3). The female proband
had two synchronous CRCs at the age of 72 years and a subsequent skin cancer at the age
of74 years . The brother of the proband (PID 12) had CRC at age 47 years but no DNA
was available for testing . Two male first cousins once removed of the proband (PID 19,
23) also were diagnosed with CRC. Bi-directional sequencing revealed that they did not
carry the c.907G>A variant. The father of these two male first cousins once removed
(PID II) had no personal or family history ofCRC. The proband of this family does not
harbour any disease-causing variants in the MUTYH gene and the proband 's tumour
sample is MSS and intact for IHC ofMMR proteins (Woods et al., 2010) .
A novel variant , c.1187A >G (p.Tyr396Cys), was identified in an individual from
family 1728 who was diagnosed with CRC at age 2 Iyears (Figure 4.4) . While neither
parent of the proband (PID 13, 14) was diagnosed with CRC, his paternal grandmother
e = CRC
+ = c.1l 87A>G
- =wild type
CRC (67)
Family 1117
CRC (62)
Figure 4.3 Partial pedigree for family 1117. No Segregation ofc.907G>A, p.Asp303Asn
GALNT12 variant with CRC phenotype . Arrow indicates proband.
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Family 1728
0#. ~o_"d:~(~) :""l '~C'Ol ~ . io "
e = CRC 12 ~+ 4~ = CRCmsTtll
+ = C 1187A>G
IS '\ 16
Figure 4.4 Partial pedigree for family 1728. The proband harboured the c.1187G >A,
p.Tyr396Cys GALNTJ2 variant. No other family member s were available for testing .
Arrow indicates proband; CIS refers to CRC in situ.
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(PID 8) and her brother (PID 7) both had CRC at age 70 years. A paternal great aunt (PID
6) presented with a malignant polyp at 55 years and a second paternal great uncle (PID 5)
was diagnosed with canc er of the stomach at age 68. Unfortunately, DNA from these
individuals was not available for testing . The MUTYHgene was not investig ated for
pathogenic variant s for this individual. The proband ' s tumour did not exh ibit mole cular
characteristics consistent with MMR mutation s (Wood s et aI., 2010 ).
4.1.2 1nvestigatingPathogenic Variants in Control Samples
Using 298 chromosomes from healthy individuals with no family history of
cancer , we sequenced exons 4 and 6 to obtain the population frequ ency of both
potentiall y pathogenic variant s, c.907G >A and c.11 87A>G . Neither variant was
identified in any of the 149 individuals tested , p= 0.039 (Fisher ' s exact test).
4.1.3 Putativelv Non-pathogenic Variants
Other GALNT12 variant s were also identified by sequencing the proband s (Table
4.1). These variants were categori zed as putat ively non-p athogenic based on three
cond itions : 1) the population frequen cy of the varia nt was greater than 1%; 2) the variant
was previously reported in the control group in Guda et al.(2009 ); and 3) the variant
codes for a synon ymous amino acid change .
The exon I variant , c.136G >A (p.Gly46Arg), was identified in I individual of the
120 probands . This variant has been previously reported in dbSNP
(httn: //www.ncbi.nlm.nih.gov /SNP /snpref.cgi?rs=10987768); however , the population
based frequency of this variant remains unknown . Guda and colleagues (2009) report ed
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that this variant reduces enzymatic activity to 99% of the WT function. This variant was
also found only in the controls included in Guda et al. (2009). Panther predicts a
subPSEC score of -2.99 and a Pdelelerious of 0.498 for this variant. PolyPhen could not
predict a possible outcome for this amino acid change . SIFT predicts this amino acid
change , p.Gly46Arg , as "tolerated". The Align GVGD classification for this change ,
p.Gly46Arg , is C65 (Table 4.3).
An exon 1 variant , c.356A>T, p.GluI19Val, was identified in 16/120 individuals
(13.3%). This variant has been reported in 1.8% of the population based on the 1000
genomes project as reported in dbSNP
(httn ://www.ncbi.nlm.nih.gov/SNP/snpref.cgi?rs=10987769). Guda and colleagues
(2009) also found this variant in their control group and functional testing revealed the
associated enzymatic activity to be 113% ofWT activity . PolyPhen predicts this variant
as "possibly damaging" with a score of 0.788. SIFT predicts the amino acid change
p.Glul19Val as "tolerated". Panther predicts a subPSEC score of -4.62 for the
p.Glul19Val change and a Pdele.eriousofO.865 . The Align GVGD classification for this
amino acid change , p.GluI19Val, is C65 (Table 4.3) .
Two individuals (1.6%) harboured a variant in exon 4, c.781G>A, p.Asp261Asn .
This variant has been reported in 0.8% of the population based on the 1000 genomes
project as reported by dbSNP
(httn://www.ncbi .nlm.nih.gov/SNP/snpref.cgi?rs=41306504).This variant was also
reported by Guda and colleagues (2009) in their control group with an enzymatic activity
of84.7% normalized to WT function. Three of the 298 (1.0%) control sample
chromosomes sequenced in this study had the c.78IG>A variant. PolyPhen predicts
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p.Asp26lAsn as "probably damaging" with a score of 0.997. SIFT predict s the change as
"tolerated" . Panther calculated a subPSEC score of -3.3 5 and a Pdeleleriousof 0.586. The
Align GVGD classification for this amino acid chang e, p.Asp26IAsn, is CI5 (Table 4.3).
A synonymous variant was identified in exon 9, c.1497C >T (p. =). One
indiv idual harboured this variant and it was previously report ed in 0.5% of the popul ation
based on the 1000 genome s project as reported by dbSNP
(http ://www .ncbi .nlm.nih .gov/SNP /snprefcgi?rs=35632007). Thi s variant was not
investigated using bioinformatic tools as it does not alter protein sequence.
Two synonymous variants were identified in exon 10, c.1707G>C and c.1734
G>A . The c.1707G >C variant has been previously reported to be in 15.7% of the
population based on the 1000 genomes project as report ed by dbSNP
(http://www .ncbi.nlm.nih.gov/SNP/snpref.cgi?rs=22 73846). This variant was identified
in 10/120 (8.3%) of the cases sequenced. The c. 1734G>A variant has not been previously
reported , but is considered to be non-patho genic based on the predicted syno nym ous
amino acid . Two individual s harbour ed this variant. These varia nts do not alter the
prot ein sequ ence and therefor e were not investigated using bioinformatic tool s.
Two variants were also identifi ed in the untran slated region (UTR) of exon 10,
c.* I71A>G and c.*421G>A. The c.*171A>G variant has been previou sly reported as
having a population based frequency of 15.7% based on the 1000 genome s project as
reported by dbSNP (http ://www .ncbLnlm.nih.gov/SNP /snpref.cgi?rs=2273847).This
variant was found in 6/120 cases (5.0%), with one individual homo zygou s for the change.
The c.*42IG >A is also a known vari ant and is reported to have a population based
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frequency of 6.4% (http://www .ncbi .nlm.nih.gov/SNP/snpref.cgi?rs=227384 8t This
variant was found in 12/120 cases (10 .0%) sequenced.
4.2 Newfoundland Color ec/al Cancer Regis/ry- Popula/i on Based Cases
After identifying two putatively pathogenic variants in exon 4 and exon 6 of
GALNT12 by investigating Newfoundland heredita ry CRC families, cases from the
NFCCR were sequenced for exons 4 and 6 to identify the frequenc y of these variant s in
the Newfoundland population-ba sed CRC cohort. Proband s that met the criteria to be in
the NFCCR, that were not previou sly referred to the Provincial Medical Genetic s
Program were included in the cohort (n=481) . Of the 481 DNA samples available , 478
(99.4%) were successfully sequenced for exons 4 and 6 of GALNTl 2. Approximatel y
47% of this cohort met the high or intermediate familial risk criteria outlined by Green
and colleagues (2007) (Table 2.1).
In total , there were seven variant s identified in 11 individual s (Table 4.5). Six
variants were found in exon 4 and one variant was found in exon 6. Of these seven
variants, two are considered to be putatively pathogenic while two are considered to be
potent ially non-pathogenic based on previous bioinformatic analysis and functional
testing (Guda et aI., 2009). For the remaining three variants, the effect the nucleotide
changes have on the protein sequence is unknown. These variants are therefore
considered to be unclassified variant s (UCVs) .
4.2.1 Putatively Pathogenic Variants
The putatively pathogenic variant, c.907G>A (p.Asp303Asn) already identifi ed in
three clinic-ba sed families, was also identified in two population -based proband s. This
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Table 4.5 Gennline variants in GALNTJ2 identified in population-based proband s
(NFCCR ).
Frequency
Variant Exon Cases Controls Population '
c.732-8G>T Intron 3 0.002 0.000 ND
c.78IG >A (p.Asp26 IAsn) 0.006 0.012 0.008
(rs4J306504)
c.857C >T (p.Thr297Mct) 0.002 0.000 ND
c.868G >T (p.Va1290Phc) 0.002 0.000 ND
c.889C>T (p.Arg297Trp)* 0.002 0.000 ND
c.907G>A (p.Asp303Asn)* 0.004 0.001 ND
c.113IG>A(p.=) 0.002 0.000 ND
' Data sourced from dbSNP [hUp:llwww .ncbi.nlm.nih.gov/project slSNPI] via Ensembl
[hUp:llwww.ensembl.org]; ND: not determined ; • Indicates variants which are considered to be pathogenic
based on previous functional testing (Guda et aI., 2009).
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variant was previously reported by Guda and colleagues (2009) to reduce enzymatic
activity to 37% ofWT function. Bioinformatic analysis predicts this variant, c.907G>A
(p.Asp303Asn), to be damaging (see section 4.1.1).
The proband from family 1148 that was found to harbour this variant was
diagnosed with CRC in the sigmoid colon at age 60 years (Figure 4.5). This individual
had no family history of CRC but had an aunt who was diagnosed with stomach cancer at
80 years of age. The CRC tumour from the proband was found to be MSS in a previous
study by Woods and colleagues (2010) . They also tested the MMR proteins MLHI,
MSH2 and MSH6 for deficiencies. These proteins were found to be intact in the tumour
of the proband. No deleterious MUTYHvariantswere identified in the proband .
The same variant, c.907G >A (p.Asp303Asn), was also found in the proband from
family 1220 (Figure 4.6) who was diagnosed with CRC in the descending colon at the
age of 69 years . The proband 's second cousin (PID 30) was diagnosed with CRC at the
age of 51 years and a first cousin once removed (PID 27) was affected with CRC at age
60. There is a strong family history of several other types of cancer, particularly of the
stomach. This proband does not exhibit any of the hallmark characteristics of LS as her
tumour is MSS with intact MMR proteins (MLH1 , MSH2 , MSH6) (Woods et aI., 2010) .
The proband also did not harbour any disease causing MUTYH variants. The family is
considered low risk for CRC as it does not meet the intermediate or high risk criteria
outlined by Green et al. (2007) (see Table 2.1).
The second putatively pathogenic variant found, c.889C >T (p.Arg297Trp), was
identified in one individual from family 1543 (Figure 4.7). This family meets the
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Family 1148
. = CRC
+ =c.907G>A
stomach ca (80)
CRC (60)
Figure 4.5 Family 1148. The proband harboured the c.907G >A, p. Asp303Asn
GALN T12 variant. No other family member s were available for testing. Arrow indicates
proband.
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Family 1220
30
CRC(SI)
• =CRC
+ =c.907G>A
Figure 4.6 Partial pedigree of family 1220. The proband harboured the c.907G>A,
p.Asp303Asn GALNT12 variant. No other family members were available for testing.
Arrow indicates proband .
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12 1\
CRC (1(f) CRC(l2)
Family 1543
. = CRC
+ = c.889C>T
Figure 4.7 Partial pedigree for family 1543. The proband harboured the c.889G>A,
p.Arg297Trp GALNT12 variant. No other family member s were available for testing.
Arrow indicates proband .
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intermediate risk-Revised Bethesda criteria; unfortunately no other family members were
available for testing. This variant was previously reported in a CRC patient from the
study conducted by Guda et al. (2009) . They reported that this variant reduced the
specific enzymatic activity to 7% ofWT function. This variant was investigated using
the bioinfonnatic tools PolyPhen, SIFT and Panther. PolyP hen predicts this variant as
"probably damaging" with a score of 0.997 (a score of 0.0 being neutral and a score of
1.0 representing deleterious changes). SIFT predicts this change as "not tolerated" and
Panther reported a subPSEC score of -7 .54 and a Pdeleteriousscore of 0.99. The Align
GVGD classification for this amino acid change, p.Arg297Trp, is C65 (Table 4.7). The
proband harbouring this variant was diagnosed with CRC in the ascending colon at age
72 years . The proband's sister (PID II) and father (PID 3) were also diagnosed with
CRC, both at age 76 years . Two maternal uncles of the proband (PID 5, 6) were
diagnosed with CRC as well (age unknown). The proband did not harbour any disease
cau sing variants in the MUTYH gene . Additionally, the tumour of the proband was MSS
and intact for MMR proteins (MLHI , MSH2 and MSH6) determined by IHC (Woods et
aI., 2010). The clinical information for individuals from the population-based CRC cohort
harbouring a putatively pathogenic GALNTI2 variant in exon 4 or 6 is presented in Table
4.6.
4.2.2 Investigating Pathogenic Variants in Control Samples
Approximately 298 chromosomes from healthy individuals, with no family
history of cancer, were sequenced in exons 4 and 6 to obtain the population frequency of
the two potentially pathogenic variants, c .907G >A and c.889C >T . Neither variant was
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Table 4.6 Putatively pathoge nic GALNT12 variants and population-based probands
clinical information,
Study # Variant Proband Age of Location of MSI !HC Family
Diagno sis Cancer Testin g ' Testing' Risk3
1148 c.907G>A, 60 Sigmo id MSS intact Low
p.Asp303A sn Colon
1220 c.907G >A 69 Descending MSS intact Low
p.Asp303Asn Colon
1543 c.889C>T 72 Ascendin g MSS intact B5
p.Arg297Trp Colon
iMSS: microsatellite stable. lIHC testing was conducted on the MLHI , MSH2 and MSH6 proteins.
lSethesda criteria: I , CRC diagnosis at less than 50 years of age; 2, synchronous or metachronous tumours
(colorecta l or HNPCC); 4, one I" degree relative with HNPCC related tumour under 50 years of age; 5, two
I" or 2nd degree relatives with HNPCC related tumours at any age. Family risk criteria are outl ined by
Green et a1.(2007) .
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ident ified in the 149 healthy individuals tested from the NL popul ation , p= 0.039
(Fisher's exact test).
4.2.3 Putati velv Non-pathogenic Variants
Several variants that were considered to be putati vely non-p athogenic were also
identified by DNA sequencing. These variant s were categori zed as putati vely non-
patho genic based on the population frequenc y of the variant greater than 1%, the variant
previousl y reported in the control group in Guda et al. (2009), and/or the variant coded
for a synonymous amino acid change .
The variant, c.78IG>A (p.Asp26IAsn), was identifi ed in three population-based
CRC case s (0.006). Thi s variant has been reported in 0.8% of the popul ation based on the
1000 genome s proje ct as report ed by dbSNP
(http://www .ncbi.nlm.nih.gov/SNP/snp ref.cgi?rs=4 1306504). Guda and colleagues
(2009) also report ed this variant in the control group with an enzym atic activity of 85%
ofWT function. Thre e of the 298 (1.0%) control sample chromoso mes sequenced in this
study had the c.78 IG >A variant. PolyPhen predict s p.Asp26l Asn as "probably
damag ing" with a score of 0.997 . SIFT predict s the chan ge as " tolerated". Panth er
calcul ated a subPSEC score of -3.35 and a PdeleteriousofO .586. The Align GVGD
clas sification for this amino acid change, p.Asp26IAsn, is C I5 (Table 4.7) .
A second putatively non pathogenic variant was identified , c.I13IG>A (p. =).
Thi s variant was identified in one individual. This variant is con sidered as putati vely non-
pathogenic becau se it causes a synonymous change . Thi s variant was not identified in the
298 chromo some s from health y control s.
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4.2.4 Unclassified VariantsruCVJ
There were three novel variants identified within exon 4 of GALNT12 that are
considered to be of unknown pathogenicity (i.e. unclassified variants, UCVs). These
variants were classified as such based on the limited information about the allele
frequency in the general population and limited information about the effect they have on
protein function .
The variant, c.732-8G >T, was identified in intron 3, eight bases before the splice site.
The effect this variant has on the correct splicing of the GALNT12 transcript is unknown.
This variant was identified in one individual that was diagnosed with CRC of the
transverse colon at 51 years . The proband belongs to family 1541 which meets the
intermediate-risk Revised Bethesda criteria (Figure 4.8). The proband 's maternal aunt
and uncle (PID 6, 7) were both diagnosed with CRC at ages 37 and 82 years , respectfull y.
Additionally, the proband's maternal grandfather (PID I) was also affected by CRC at
age 65 years . This proband had an MSS tumour and the MMR proteins (MLH 1, MSH2
and MSH6) were intact. The proband of this family does harbour a heterozygous, known
pathogenic, variant in the MUTYH gene, p.Gly382Asp.
A second UCV was identified , c.857C>T (p.Thr286Met). This variant was
identified in the proband from family 1595 who was diagnosed with CRC in the
descending colon at age 60 years . This family meets the high-risk AC-I criteria (see
Figure 4.9). The proband's sister (PID 13) was diagnosed with "a cancer of the abdomen"
at age 26 years ; the proband's father (PID 8) was diagnosed with CRC at age 24 years.
There was also a paternal uncle of the proband (PID 5) who was diagnosed with CRC
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Family 1541
10 "
CRC (SO)
. = CRC
+ = c.732-8G>T
Figure 4.8 Partial pedigree for family 1541. The proband harbour s the c.732-8G>T
variant. The proband also harbours a known pathogenic variant in the MUTYHgene. No
other family members were availabl e for testing . Arrow indicates proband.
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Family 1595
12 '\
CRC (6O) C1abdcmtn(26) • =CRC
+ =c.857C>T
Figure 4.9 Partial pedigree for family 1595. The proband harboured the c.857C >T,
p.Thr286Met GALNTJ2 variant. No other family members were tested as this family has
been diagnosed as having Lynch Syndrome-the proband harbours the pathogenic MLH1
c793C >T variant. Arrow indicates proband .
(age unknown) and also two maternal uncles (PID 10, II ) diagnosed with CRC (age
unknown). The tumour from this proband was found to be defic ient in the MLHI protein
and was also found to have microsat ellite instab ility (MSI). This individual harboured a
pathogenic variant in MLHl , c.793C>T (Woods et al., 2010). The GALNT12 variant ,
c.857C>T (p.Thr286Met), has not been previously report ed in dbSNP . Bioinfonnat ic
analysis was conduct ed to determine the effect this variant has on protein function .
PolyPhen predicts p.Thr286Met to be "probably damaging" with a score of 0.998. SIFT
predicts the change to be "not tolerated" and Panther calculat ed a subPSEC score of -2.83
and a Pdeleteriousof 0.456. The Align GVGD classification for this amino acid change ,
p.Thr286Met, is C65 (Table 4.7).
A third UCV, c.868G>T (p.VaI290Phe) , was identifi ed in one individual. This
proband is from family 2287 which is considered to be a low risk family (Figure 4.10).
The individual harbourin g this variant was diagnosed with CRC at age 64 years. The
father of the proband (PID I) was diagno sed with pancreatic cancer at the age of8 1
years. The proband ' s brother (PID 5) was diagnosed with lung cancer at age 56 years.
The proband' s tumour is MSS and intact for the tested MMR proteins (MLHI, MSH2
and MSH6). The proband also does not harbour any disease causing variant s in the
MUTYHgene. Bioinfonnatic analysis was conducted to determine the effect this variant
has on the function of the protein. PolyPhen predicts p.Val290Phe to be "probabl y
damaging " with a score of 0.967. SIFT predicts the change to be "not tolerated " and
Panther calculated a subPSEC score of -4.71 and a PdeleteriousofO.847. The Align GVGD
classification for this amino acid change , p.VaI290Phe , is C45 (Table 4.7).
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Table 4.7 Bioinfonnatie an alysis of non synonymo us GALNTl2 variants identified in population-based probands (NFCCR).
Bioinfonnatie Tool s
Variant Exon SIFT 1 Polyl'hcrr ' Panther ' Align
(Predietion, Pdeleteriou,) (subPSEC, Pdeletet;ou,) GVGD 4
e.78IG>A (p.Asp26IAsn) 4 TO PrD ,0.997 -3 .35 ,0.586 C I5
e .857C>T (p .Thr2 86Met) 4 NT PrO , 0.998 -2 .82 ,0.456 C65
e.868G>T (p .VaI290Phe) 4 NT PrO, 0.967 -4 .71 ,0.847 C45
e .889C>T (p .Arg297Trp) 4 NT PrO , 0 .997 -7 .54,0.989 C65
e.907G>A (p .Asp303Asn) 4 NT PrO, 0.999 -9.2 8,0.998 CI5
IT O: tolerated; NT : not tol erated. 2psD: po ssibly dama ging; PrO : probably damaging. 3 subPSEC: the "negative logarithm of the
probability ratio of the wild type and mutant amino acids at a particular position" (Brunham et aI., 2005). These scores arc continuous
values that range from 0 (mostly likely benign) to -10 (most likely pathogenic ). ). 4Classifieations arc listed from most likely to interfere
with protein function to least likely; C65 (most likely), C55, C45, C35, C25, C15 , CO(less likely).
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Family 2287
. = CRC
+ = c.868G>T
CRC (64) lungca(56)
Figure 4.10 Partial pedigree for family 2287 . The proband harboured the c.868G >T,
p.Val290Phe GALNT12 variant. No other family member s were available for testing .
Arrow indicates proband.
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Chapter 5
5.0 Discussion
5.1 Clinic-based Cohort Summary
In total, three putatively pathogenic GALNTl2 variants were identified in five
probands . Partial segregation of one of these variants with the disease phenotype was
observed in two of the five families identified . A number ofUCVs were identified which
may also contribute to the onset ofCRe. The results from the clinic-based portion of this
study has been recently published (see append ix D, Clarke et aI., 2012).
The clinic-based study identified two putatively pathogenic GALNT12 variants,
c.907G >A and c.1187A >G. The c.907G >A variant was identified in four probands and
was found to segregate in two of the four families identified . This variant, c.907G>A,
was previously reported in a study by Guda and colleagues (2009) to reduce enzymatic
activity of the protein to 37% ofWT function. Bioinformatic analysis also shows that this
variant is predicted to be pathogenic (Table 4.8). Although the variant only partially
segregated with the disease phenotype (some carriers not having the disease phenotype
and some non-carriers diagnosed with CRC and/or adenomatous polyps), the SISA
results revealed that the probability of co-segregation by chance, in both families (20444
and 20896), was 1.56%, indicating that this variant is likely associated with the disease
phenotype observed . SISA is used to identify which lineages an unclassified variant is
segregating in a hereditary cancer family. It also estimates the probability of chance co-
segregation and can also be used to estimate the penetrance and/or expression .
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Multiple individuals from family 20444 harbour the c.907G >A variant. When
adenomatous polyps are included in the disease phenotype; four individuals (Figure 4.1)
are affected in this family. Adenomatous polyps are considered to be an indication that an
individual is at higher risk for developing CRC as these polyps have potential to progress
toCRC.
All four affected individuals harbour the c.907G>A change. In addition, four
other unaffected individuals (i.e. not diagnosed with CRC or adenomatous colonic
polyps) also harboured the c.907G>A variant. It is worthy to note that the unaffected
carriers are approximately 5-10 years younger than the affected carriers (unaffected
carriers median age 54.5, range 50-60 years of age). It is possible that these individuals
are at increased risk for developing CRC at a later age. It is also likely that the c.907G >A
variant is not 100% penetrant. In summary, four affected and four unaffected individuals
harbour the GALNT12 variant, c.907G >A, and one individual with an unknown polyp
type was negative for the variant. Through the use of SISA, we determined that the
probability of co-segregation by chance with the disease phenotype was only 6.25%.
These findings show support for the association between GALNT12 and hereditary CRC
in this family (20444) .
Family 20896 also had multiple individuals that harboured the c.907G >A variant.
If adenomatous polyps are included in the disease phenotype, a total of seven individuals
are affected in this family. DNA was only available for four affected individuals as well
as two individuals that were not affected. Three of the four affected individuals with
available DNA carried the c.907G >A variant. One individual (PIDI8), who was affected
with CRC at age 57, did not harbour the change. This individual was a son of an affected
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mother (PID 7) who mayor may not have carried the variant (DNA not available) . It is
possible that this affected non-carrier (PID 18) is a phenocopy (sporadic case) due to the
high incidence of the disease in the overall population. Although finding an affected non-
carrier somewhat weakens the argument for the involvement of GALNT12 contributing to
hereditary CRC within this family, three of the four affected individuals were carriers and
two unaffected individuals were non-carriers . Additionally, the SISA analysis revealed a
25% probability that this variant co-segregated with the disease by chance. Overall , this
family provides some evidence supporting the role of GALNT12 in hereditary CRC .
Family 1728 provides little evidence for or against the association between
GALNT12 and CRC due to the fact that DNA was not available from other affected
family members. The proband was young at the age of diagnosis (21 years) which is
suggestive of genetic influences on CRC; however, the variant found was novel and has
not been shown to be involved in with the disease. Bioinformatic analysis did, however ,
predict this variant to be pathogenic (Table 4.3). Functional testing should be conducted
to define the effect this variant has on enzymatic function . More information is needed
about the inheritance pattern of this variant within the family and the effect this variant
has on protein function, to conclude ifit is responsible for the presence of hereditary
CRC in this family .
Four individuals from family 1117 were affected with CRC, three of whom had
DNA available for testing. The proband carried the c.907G >A variant while the other two
affected individuals, who are second cousins of the proband, did not (Figure 4.3). The
possible involvement of GALNT12 in the onset and progression of hereditary CRC in this
family is difficult to interpret. It is possible that a different unknown genetic
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predisposition is the underlying cause of CRC in this family, and the GALNT12 variant
identified in the proband is contributing exclusivel y to her observed phenotype .
The study by Guda and colleagues (2~09) revealed findings that support the
association between GALNT12 and colon cancer . Several linkage and association studies
have provided evidence for a gene responsible for CRC at the chromosomal region near
GALNT12 (9q22) (Wiesner et aI., 2003; Kemp et aI., 2006; Skoglund et aI., 2006 ; Gray-
McQuire et aI., 2010). The present study is the first to use family-based studies to
investigate the contribution ofGALNT12 to familial CRC. Two families that showed
partial segregation ofa variant , c.907G>A, with the disease phenotype. SISA revealed the
probability by chance of co-segregation of c.907G >A with the disease phenotype , in both
families , was 1.56%. This indicates that the variant , c.907G>A, occurring in these
families is likely (98.44%) associated with the disease phenotype . The four individuals ,
from family 20444, that harbour this variant and have not had a history of CRC or
adenomatous polyps can be explained by the late onset of the disease or incomplete
penetrance of the variant. Guda and colleagues (2009) reported the average age of onset
for CRC in cases identified with a causal GALNT1 2 variant was 71.5 years . The four
unaffected individuals identified with the c.907G>A variant in family 20444 had an
average age of 54.5 years . It is possible that these individuals are at a higher risk for
developing CRC later in life.
It is probable that if there was more DNA available from the family members
included in the present study , the results may have been more conclusive in determining
the impact GALNT12 had on the disease phenotype . The results of this study were not as
compelling as those from Guda et aI., (2009) as they used functional testing to confirm
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the presence of pathogenic variants and these pathogenic variants were only identified in
cases and not controls . Although our results are not as convincing as those in Guda et al
(2009), they are somewhat impactful as we did identify two putatively pathogenic
variants in four affected individuals accounting for approximately 3.33% of the clinic-
based study population .
Due to the novel association of GALNTJ2 and CRC, the exact phenotype and
types of cancers involved in this disease pathway remained to be determined. It is
possible that GALNT12 may be involved in other types of epithelial cancers. In the
present study, the sister of the proband from family 20444 (PID 4; Figure 4.1) was
affected with skin cancer at age 82. The sister of the proband from family 20896 (PID 8;
Figure 4.2) was reported to have stomach cancer between the ages of 77 and 79 years
(exact age unknown) and also had a subsequent mass in her transverse colon at age 82
years. The proband from family 1117 (PIDI8; Figure 4.3) who harboured the c.907G >A
variant was also affected with skin cancer at age 74 years. Additionally, the paternal
great uncle of the proband from family 1728 was diagnosed with stomach cancer at age
68 years . Furthermore, the study by Guda et al. (2009) reported having access to
complete medical records from three cases that had an identified inactivating germ line
GALNTJ2 variant. Each of these three individuals were reported to have been affected by
two independent epithelial cancers which included independent synchronous CRC and
multiple reports of breast cancer. It is possible that other extra-colonic epithelial cancers,
such as stomach, breast and skin cancer are associated with the putative GALNTJ2
pathway .
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In summary , the results of the familial analysis provides partial evidence for the
involvement of GALNTJ2 in hereditary CRC; however, they do provide findings which
strongly suggest that this gene should be further investigated to determine its impact on
the onset and progression of this disease.
5.2 Population-Based Cohort Summary
A total of seven variants were identified by sequencing exons 4 and 6 in 478
individuals diagnosed with CRC. Exons 4 and 6 were selected for sequencing based on
the findings from the clinic-based cohort. Two of the seven variants identified in the
population-based probands have been considered to be putatively pathogenic based on
previous findings (Guda et aI., 2009).
The variant c.907G >A has been previously reported in CRC cases in the Guda
study (2009) . Through functional testing , Guda and colleagues (2009) found that this
variant reduces enzymatic activity to 37% ofWT function. Bioinformatic analysis also
shows that this variant is predicted to be pathogenic (Table 4.8). This variant was the
most frequent variant observed in both the population-based cohort and clinical-based
cohort , being identified in a total of five CRC cases. This variant was not identified in
any of the 149 healthy controls tested. It is worthy to note that 272 controls were initially
sequenced in exons 4 and 6. One individual of the initial 272 controls harboured the
c.907G >A variant. The control individual (age 65 years) that harboured this variant had a
family history of epithelial cancer (Figure 4.11). Since mutations in GALNTJ2 may cause
others cancers too, all controls with a family history of cancer were removed from the
study. As mentioned above , it may be possible that GALNTJ2 pathogenic variants cause
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Control Family 40994
+ = c.907G>A
Figure 5.1 Partial pedigree for control family 40994. The control individual harboured
the c.907G >A, p.Asp303Asn GALNT12 variant. No other family members were available
for testing. Arrow indicates control individual.
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extra colonic carcinoma s just as MMR pathogenic variants do in LS (Lynch et aI., 2009) .
Therefore , this control individual may be at an increased risk for CRC or other
carcinomas . Unfortunately DNA was not available from the family members of the
population-based probands who harboured GALNT12 variant s. This DNA would have
been useful in investigating the inheritance patterns of the variants identified , in addition
to penetrance and variable expres sion patterns .
The second putatively pathogenic variant found in this cohort , c.889C>T, was
identified in one individual. This variant has been previously reported by Guda et al.
(2009) and functional testing revealed that this variant reduces enzymatic activity to 7%
of the WT protein function. Bioinformatic analysis also predicted this variant to be
pathogenic (Table 4.8). Based on Guda et al (2009) , together with the bioinformatic
analysis , this variant has been classified as putatively pathogenic . Unfortunately, DNA
was not available from the family members of the proband to determine if the variant
segregated with the disease phenotype .
There were several UCVs identified in the population based cohort . It was
decided that bioinformatic analysis alone was not sufficient to classify a variant as
pathogenic . More information is needed to conclude whether these variants significantly
affect the function of the GALNT12 protein and therefore all three UCVs should be
further investigated by cDNA analysis and enzyme activity assays . cDNA analysis should
be used to determine whether the c.732-8G >T variant , found in family 1541, affects
splicing at the 3' end of intron 3. Enzymatic assays similar to those conducted by Guda et
al. (2009) should be conducted for all three UCVs. It is possible that the c.857C >T
variant contributed to the CRC phenotype observed in the proband from family 1541;
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however, it is probable that this variant is not the main predisposition causing CRC in this
patient as this individual also harboured a pathogenic MLHI variant, c.793C>T. The
effect the c.857C>T GALNTl2 variant has on protein function should still be investigated
to determine if this variant has an additive effect on the CRC phenotype observed in this
family.
With advancements in technology providing increased opportunity for molecular
genetic testing there has been a rapid increase in the identification of novel variants with
unknown pathogenicity. Analysis of co-segregation ofUCVs in high risk CRC families is
a powerful approach to determine if the variant is pathogenic. Bioinformatic analysis
based on amino acid conservation and physical properties is another approach used to
determine the pathogenicity ofUCVs. Case-control studies also provide frequencies of
UCVs in both populations allowing for an estimation of whether the UCVs occur more in
the disease population compared to the healthy population. Functional studies are also a
useful approach to determine if a UCV is affecting the function of the protein .
Specifically, the function of GALNT12 can be measured through enzyme activity assays
using transferase bound beads to measure the relative transferase activity compared to
WT GALNTl2 protein transferase activity (Guda et a!., 2009). eDNA analysis is also
another way to determine if the proper transcript is being transcribed when a potential
splice-site variant is identified. While each of the above approaches have limitations,
using these analyses together is an appropriate way to determine pathogenicity ofUCVs.
In total, three cases out of the 478 included in the study were identified as
harbouring putatively pathogenic variants accounting for 0.623% of the total CRC
population studied . If these putatively pathogenic variants are truly pathogenic, the
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proportion of CRC cases that the GALNT12 variants account for in this study are
comparable to that of FAP or MAP, which account for I% and < I% of all CRC,
respectively (Bisgaard et al., 1994; Croitoru et ai, 2004; Fleischmann et ai, 2004; Wang et
ai, 2004; Farrington et ai, 2005) . It may be possible that some of the UCVs identified are
pathogenic , increasing the proportion of CRC cases accounted for by GALNT12 causal
variants. Additionally , it is likely that more individuals would have been identified with a
GALNT12 pathogenic variant ifexons 1,2,3,5,7,8,9 and 10 were also investigated .
Furthermore, it may be possible that screening for large exonic deletions and duplication s
through multiplex ligation-probe amplification (MLPA) analysis would uncover
additional CRC cases.
5.3 GALNT12: The Potential Rol e in CRC
This study provides some evidence for the involvement of GALNT12 in familial
CRC. This data should encourage others to further investigate GALNT12 variants in both
clinical and populat ion-based cohorts . If GALNT12 is involved in the development of
CRC it could be associated with the increase in improperl y glycosylated or
unglycosylated MUCI proteins in the human colon. Guda and colleague s (2009) did find
increased levels ofunglycosylated MUCI proteins in three out of three patients for which
they had tumours available.
Mucin proteins are important for mucus production and providing a protective
layer over the epithelium (Brockhausen , 2006) . O-glycans make up over 50% of the total
molecular weight of a mucin molecule . Glycosylation of mucin proteins is important for
the maintenance of protein structure. It is possible that the protective function of the
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mucin proteins may be compromised if the proper glycosylation of these proteins is not
met. Ifpathogenic variants in GALNT12 are associated with reduced glycosylation , it
could be that this reduced glycosylation causes a reduced functional protection of the
epithelial layer, therefore causing CRC to form in the epithelial cells that line the colon.
Additionally , it has been noted that aberrant glycosylation can influence the growth and
survival of a cell and its ability to metastasize (Brockhaus en, 2006) .
5.4 Study Limitations
There were a number of limitations in this study. First, both cohorts were
investigated only for exonic point mutations . It is possible that a number of individuals
included in the study may harbour large exonic deletions or duplications that would not
have been identified through the methods used in this study . Second, cDNA analysis was
not conducted to determine if the c.732-8G>T variant affected the correct splicing of the
transcript. Third, in both cohorts , not all the affected family members of proband s
identified with a GALNT12 variant had DNA available for testing. Not being able to test
all affected individuals in the family limits the results and the ability to be conclusive
about the segregation of the variant with the disease. Additionally, the validity of the
bioinformatic tools used must be questioned as the algorithms sometimes give conflicting
results . Bioinformatic tools should be used with caution and in conjunction with
functional testing , segregation analysis or case-control analysis. Functional tests, such as
enzyme activity assays used to deduce if the identified variants actually affected the
enzymatic function of the GALNT12 protein, were not performed in this study.
Furthermore, IRC analysis investigating the proportion of properly glycosylated MUCI
protein within the colon tumours of individuals with GALNT12 variants, as conducted by
85
Guda et al (2009), might have yielded more data to evaluate the variants identified in
GLANT12 . It is possible that glycosylation is not the only function of the GALNTl2
protein. If this protein has other functions , variants in this gene could affect the addition al
functions of the protein . Thus enzymatic assays, employed by Guda et aI., (2009)
measuring glycosylation, may not have been effective in determining other functions of
GALNTl2 within the cell that could be contributing to the onset ofCRC. Finally, any
variants that were >30 bases into the intron were not assessed because they were not
captured with the methods used. Such variants may have an effect on cryptic splice sites
or other regulatory elements playing a role in expression and translation of this gene.
5.5 Future Studies
While the results of these two studies are not conclusive , they do suggest that
further investigations into the role of GALNT12 in CRC should be conducted . Future
studies should include investigating all exons of GALNT12 in population-based cohorts
as well as determining if deletions and amplification mutations occur. Functional testing,
cDNA analysis and studies that investigate large insertions , deletions and duplications
should also be considered.
Further studies are needed to better understand the relationship between
GALNT12 and the onset and progression ofCRC. Studies investigating GALNT12 have
the potential to provide data for knowledge translation from the laboratory to clinicians
and patients , thus having a significant impact on survival , prevention and treatment of
inherited CRC.
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Chapter 6
6.0 Conclusion
In this study, two of four families harbouring a putatively pathogenic GALNT/2
variant had the variant segregate with CRC within their family. While there was only
partial segregation of the variant with the disease phenotype , SISA revealed that the
probability of co-segregation by chance was low, 1.56%. This study is the first to
investigate the inheritance of GALNT/2 variants in hereditary CRC families .
The population-based study produced interesting results as it identified two
pathogenic variants previously reported by Guda and colleagues (2009) in addition to
identifying a number ofUCVs that could also be important in the onset and progression
ofCRC.
Currently , there is a significant proportion of hereditary CRC that remains
unsolved . Discovering a new genetic cause of hereditary CRC would add to the
understanding of the etiology of this disease. While previous studies indicate an
association between CRC and GALNT/2 (Guda et aI., 2009 ; Gray-McQuire et aI., 2010) ,
the role ofGALNT/2 in hereditary CRC remains unclear . Future studies should continue
to investigate the inheritance of GALNT/2 variants to yield more conclusive results about
this gene and its role in hereditary CRC.
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Appendi x A: Amsterdam Criteria
Amsterdam Criteria I (AC-I)
• Three relatives with CRe plus all of the following:
- One affected 1st degree of other 2
- Two successive generations affected
- One diagnosis at < 50 years
- FAP excluded
- Tumours verified by pathological examination
Amsterdam Criteria II (AC-II)
• Three relatives with Lynch Syndrome' related cancer and all of the following :
- One affected first degree relative of the other 2
- Two successive generations affected
- One diagnosis at age <50 yrs
- FAP excluded
- Tumours verified by pathological examination
'Ly nch Syndrome related cancers include; endometrial/uterine, small bowel, kidney and
ureter
Appendix B: Revised Bethesda Criteria
Tumors from indi vidual s should be tested for MSI in th e following situations:
I. Colorectal cancer diagnosed in a patient who is less than 50 years of age.
2. Presence of synchronous, metachronous colorecta l, or other LS associated tumors I,
regardless of age.
3. Colorectal cancer with the MSI-H histology diagnosed in a patient who is less than
60 years of age.
4. Colorectal cancer diagnosed in one or more first-degree relatives with an LS-related
tumor I , with one of the cancers being diagnosed under age 50 years.
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with
LS-related tumors' , regardless of age.
ILynch Syndromerelatedcancersinclude;endometrialluterine ,ovarian, small bowel,
pancreatic, kidney , ureter,hepato-biliary, brain and lymphoma
Appendix C: GALNT12 Primer Sequences
Exon Forward Primer
5' -CTGCCGAAATGAGCCAC-3'
5' - GTCCCCTTTGTCACTCCATC-3'
5'- ACAGGGAGGCCCAGAAGG-3'
5' - TGAA TTTCCCAATTGTCTTCC-3'
5'- TCGTGGTGGGAAGGTAGTTG-3'
5'- GGCCTCTTTGCTGCAGATAC -3'
5' - CAGTGAACACAGGGGCTTTG-3 '
5'- TCTTGAAGCAGGCTCTCCTC -3'
5' - TTGTCCAGCGATCTTTCCTC-3'
lOa 5'- CTGCGITACACGGAAGACACT-3'
lOb 5'- AAACTAGGCTGCATTGCTTTG-3'
Reverse Prim er
5' -GCGGTCGCTGAGGTAGA TG-3'
5' -CTGGGCCTACTTTAGCCCTC -3'
5' -TGA TGAGTCTGTTCCTCATGC-3'
5'-ACAGCT AACCATTCCTCCCG ·3 '
5' -GGTCCACCAGGCTCTTACAG- 3'
5' -CCAGA TCGACTATGTTGGGG-3'
5' -CATGACGTGGCCTTTCTTG-3 '
5' -TGGCCACCCT AGGCTTCT AC -3'
5' -CCTCACCAGGACTATGCCAG-3'
5'-TACGAITACCCTTTGAAAATAGG-3'
5' -GGAAAACTTTAACCCCGCAG-3 '
IOc 5' - CAAGAATTCCCAGGT ACGAAG-3' 5'CA TTTCTCCCTGACACTACCG-3'
IOd 5'- GAGAACAATTTGCTTTACTAAGCTG -3'5 '-CAAGTGATCTGCCCTCCTTG-3 '
Appendix D: Inherited Deleterious Variants in
GALNT12 are Associated with CRC Susceptibility
See attached document.
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ABSTRACT: A recent report detailed the occurrence of
both somatic and constitu tional variants in th e GALNT1 2
gene, located at9q22.33, inso me colorecta lca nce r( CRC)
patients. In this study, we investigate the occurrence
of inherited deleteriou s variants in GALNT12 in 118
familie s referr ed to a cancer genetic s clinic . Wediscov..
eeed two deleteri ous variant s (c.907G>A (p.A sp30 3A sn);
c. 1187A>G (p.T yr3 96Cys») in 4/11 8 proband s, Th e
varia nts , which were not found in 149 control individuals
(P = 0.03 76), cosegrega te with C RC and/or adenoma-
tous polyps in othe r family members. The probabilit y by
chance that cosegregatio n of c.907 G >A with CRC and/ or
adenomatous polyps occurre d, in th e two pedigrees com..
bined, was 1.56 %. Alth ou gh thi s study does not pro vide
irrefutable evidence that GALNTI2 variants are highly
penetrant alleles th at predispose to CRC in the major.
ity ofunexplain ed hereditary CR C families, it does pro-
vide addit ional evide nce to support an important role of
these variants in a proporti on of th is con siderable high.
risk group.
HumMutat OO:l - 3, Z012. C 201 2Wi leyP eriodicals,In c.
KEYWORDS: GALN T I2; her edita ry colorecta l cancer;
CRC ; Newfoundl and
In about 5% of colorectal cancer (CRC) patients, a strong family
history can be explained by highly penetrant alleles occurring in any
of several well-characterized genes but, in many other such famili es.
the genetic basis remains obscure.
The g1ycoproteins ofcoloreetal tumo rs are often qual itatively
or quantitatively abno rmal. In a 2009 study of colorectal tu rnors,
Gudae t al. [2009J described finding deleterious variants in a gene
coding for an enzyrne involved in the O-g1ycosylation of mucin-
typegl ycans.Thi se nzyrne, N.acetylgalactosaminyltransferase-type
Contractgrantsponsors:NationaICancerlnstitutaofCanada(l8223,18226); Canadian
InstitutesofHealthResearch ICRT-438211; GenomeCanadaIAtlantic MedicalGenetics
andGenomics lnitietive}
12 (GALNTl 2), is expressed at high level in the normal colon [Guo
et aI., 2002J. Guda et al. [2009J found seven deleterious germlin e
variants in CALNT I2 (MIM# 610290) in coloreetal cancer (CRe)
patients . which were not found in a cont rol gro up. However. no
infor mation was available on the family histor y of the CRC pa-
tients carryi ng these germline CALNT I2 variant s. We now repor t
on the occur rence of CALNT I 2variants in a cohort ofC RC families
referred to a cancer genetics d inic.
Newfoundland and Labrador (NL) has the highest incidence of
CRC in Canada [Canadian Cancer Statistics, 20 llJ , being 49%
higher than the Canadian average. Investigations ofa large coho rt 0 f
consecutive NLCRC patients revealed a high frequency of familial
CRC that may be attr ibutable to as yet undi scovered susceptilfil-
ity genes [Green et al.• 2007; Woodset aI.,20 1O].Give n th is high
incidence of unexplained familial CRC, we decided to determin e
the occur rence of CALNT I2 variants in the pro bands of 118 CRC
families, which had been referred to a genetics clinic because of an
extensive family history of CRC and/o r CRC diagnosis at a young
age.
Approxi mately 22% (n = 26) of the pro bands met the Amsterdam
I criteria and the remain ing 78% (n =92 ) met the revised Bethesda
criteria [Uma r et al., 2004; Vasen et al., 1991J. Family member s
gave informed consent to be included in CRC studies and prov ided
a blood sample and access to tissue samples and medical record s.
Ethical approval was obtained from Memori al University's Hu man
Investigation Comm ittee. Primer sequences for each ofth elO exons
of CALNT I2 were described by Guda et aI. [2009]. All exons and
intro n/exon boun daries were screened for variant s using standard
prot ocols for auto mated direct sequencing. Prim er sequences and
PCR conditions are available upo n requ est. PCR products were
sequenced ona n ABISequencer3 130XLandd ata was analyzed using
Sequencing Analysis 5.2 and Sequencher 4.9. All variants identified
are described in Supp. Table Sl.
In total, two pathoge nic variants were identified in proban ds
from four different families (Table I andSupp. TableSI ). Three
individual s harbored a c.907G>A (p.Asp303Asn) variant,previously
reported by Guda et al. [2009] toreduce enzyrnatic aetivity t0 37%
of the wild-type protei n. One indiv idual harb ored a novel variant.
c.1187A>C (p.Tyr396Cys).
The pro band of family 20444 (Fig.I ),di agnosed withreetal can -
cer at age 35 years. carried the c.907G>A (p.Asp303Asn) variant .
Her sister, who was diagnosed with CRCat age 61 years. carries
the same CALNT I2 var iant, as do six of the sister's eight chil-
dren who were available for testing. In this sibship. adenoma tous
polyps were identified in 2/6 offspring that had undergone clinical
screening- both of whom are carriers (Supp. Table S2). A1l variants
have been submitted to the LOVD CRC database (www.lovd.nU
GALNT I2).
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Summary Data from the CRCProbandswith Deleterious Germline GALNTt2Varian ts
Proband age MSI (M~~~.t:~~g2:~~~6)of diagn osis (CRC) testing result" PolyPhend
c.907G>Ap .Asp303Asn 2. '
c.907G>A p.Asp303Asn ' . S
1728
c.907G> A p.Asp303Asn
MSS Intact
2.5
PO NTc.1l87A>G p.Tyr396Cys
· Variant nomenclature is basedupon the reference sequence NM_02-4642.4. Nuclec tide num~ring rd]tctscDNAnum~ring with + l corrtsponding toth(' A ofth('ATG
~~~~~~~:~::~::s~~~~rt:o~e;:=i~~U~DNA sequencing of MLHI . MSH1. and MSH6did not reveal any deleterious variants;
creviscd.Bdhesda criteria l, CRCdiagnosis at les.slhan SOyean ofage;2, synchronousor metachro nous tum ors (colorectal or HNPCC· r'C'lated tu mor ); 4, one first-degree
relative with HNPCC· related tumor und er SOytarsof age;S , two first-o cs«ond..<Jegrtt rd ativeswith HNPCC-rtlatedtum on atan y age.
dPD,probablydamaging.
~NT. not tolerated. Additionalnonpathogenic variants wcrealso identified (5upp.Table 51).
Figure l. Twofamilies segr egating the c.907G>A GALNT12 variant Arrows indicate probands. Numbers in brackets refer to ages of diagnoses
(Hyp, hyperplastic polyp; Adn. adenomatous polyp; 1. polyptype unknownl.Additional clinical information can be found in Supp. Table S2.
The proband of family 20896 (Fig. I) also carrie s the c.907G>A
varian t and he presented with mul tiple polyps and was first diag-
nosed with CRC at age 72 years. Two daughter s also carr ied the
variant : one (PID 12) develop ed CRC at age 57 and the second
(PID I4) has had two adenomas removed,both at age 45 years. A
third daught er (PID I3) did not carry the variant and had two hy-
perplastic polyps at 54 years of age. DNA was not available from two
CRC-affecteds isters of the proband, although aso no f one of them
(PID I8) had CRC at age 57 years, yet did not carry the GALNT1 2
variant and may thus represent a pheno copy.
Neither family 20444 nor 20896 met the Amsterdam crite ria,
possibly because screeningcolonoscopie s identified precancerou s
polyp s in several of tho se at risk.
The third proband (family 1117) harboring the c.907G>A
(p.Asp303Asn) variant also fulfills the revised Bethesda criteria and
had two CRCs at the age of 72 years, followed by skin cancer at the
ageof 74 years. The brothe r of the proban d had CRC at age 47 years;
however, no DNA was available for testing .
A novel variant, c.1187A>G (p.Tyr396Cys), was identi fied in the
proband ofa fourth family (family 1728). He also fulfills the revised
Bethesda criteria and was diagnosed with CRC at2 1years ofage. The
father of the proband has not been diagno sed with cancer ; however,
the proband's paternal grandmother and his paternal great uncle
both were diagno sed with CRC at age 70 years. Unfortunately, DNA
was not available for any family member other than the proband ,
so segregation analysis was not possible. While no functi onal test-
ing dat a is available, we conducted bioinform atic analyses on th is
var ian t and it was predicted to be patho genic (PolyPhen [Sunyaev
etal., 2001), SIFr [Ng and Hen ikoff, 2003)). Likep.Asp303Asn,
p.Tyr396Cys lies in an imp ortant functi onal dom ain (catalytic) of
the protein .
This is the first study to identify inherited deleterious GALNT 12
variant s that segregate within families that appear to have an in -
heritedform ofCRC. We ident ified such variants in 41118 (3,4% )
familie s studied. We then sequenced GALNT1 2 exons four and six
in DNA from 149 health y ind ividual s from the NL popula tion . The
controls were initially contacted by phone throu gh rand om digit di•
aling and were obtain ed for a popul ation -based CRCs tudy [Woods
etal.,201O ]. They are all Caucasian, from NL,consented to have
blood draw n, completed a family history questionnaire and had
no known history of any cancer in first-degree realtives. Neither
variant was found in thecontrols,P =0 .0376 (Fisher's exact test).
To determine if segregation of these variant s in families 20444 and
208960ccurredbychance,weemployedsimplifiedrapid segrega-
tio nanalysis (SISA) [Moller et al.,2011 ]. Thus, we determined that
the probability by chance that cosegregation of c.907G>A with CRC
andJor adenomatous polyps occurred ,in both pedigrees combined,
was 1.56% (6.25% for 20444 and 25% for 20896).
Multip le linkage and association studie s [Gray-McGuire et al.,
2010; Kemp etal ., 2006;Sk og!und et al., 2006; Wiesner et al.,2003 )
have together provided strong eviden ce for a CRC-susceptibility
gene in the chro mosom e region where GALNT 12 is located. This
study, together with the initial report from Guda et al. (2009), suggest
that deleterious alleles in GALNT12 can account for a proportion
of that considerable group of CRC families in which the known
CRC-associated genes have been exduded . Such variants may also
increase the risk of other epithelial cancers [Guda et al.• 2009).
It is possible that more extensive analyses. such as scanning for
largeexonic insertion sldeletions or for regulatory variants wiUun -
cover additional families harboring deleterious variants in our clin-
icalcohort. Future studies should focus on estimating the frequen cy
of GALNT 12 variants in large popula tion -based cohorts and should
also estimate the penetrance in families that harbordeleteriousvari-
ants in GALNT 12.
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